|
<?xml version="1.0" encoding="UTF-8" standalone="yes"?> |
|
<tmx version="1.4"> |
|
<header adminlang="en" creationdate="20200424T153634Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="sl"> |
|
<prop type="distributor">ELRC project</prop> |
|
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop> |
|
<prop type="l1">sl</prop> |
|
<prop type="l2">en</prop> |
|
<prop type="lengthInTUs">491</prop> |
|
<prop type="# of words in l1">7633</prop> |
|
<prop type="# of words in l2">7524</prop> |
|
<prop type="# of unique words in l1">1545</prop> |
|
<prop type="# of unique words in l2">2353</prop> |
|
</header> |
|
<body> |
|
<tu tuid="1"> |
|
<prop type="lengthRatio">0.972972972972973</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje je edini način za zagotovitev neposredne zaščite proti tetanusu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="2"> |
|
<prop type="lengthRatio">1.0555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Temu rečemo „kolektivna imunost" (z drugo besedo tudi „čredna imunost").</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="3"> |
|
<prop type="lengthRatio">0.8921568627450981</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S tetanusom se na primer lahko okužimo pri čisto navadnih poškodbah, vključno ob ugrizu psa ali mačke.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="4"> |
|
<prop type="lengthRatio">0.9893617021276596</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Programi imunizacije poleg tega zmanjšujejo družbeno, psihološko in finančno breme bolezni za prebivalstvo in vlade, zmanjšujejo pritisk na sisteme zdravstvenega in socialnega varstva in omogočajo ljudem udejstvovanje v produktivnih dejavnostih, kot sta izobraževanje in zaposlitev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="5"> |
|
<prop type="lengthRatio">1.1150442477876106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za vzpostavitev kolektivne imunosti na ošpice pristojni organi za javno zdravje priporočajo, da je treba cepiti 95 % prebivalstva z dvema odmerkoma cepiva proti ošpicam (cepivo MMR za zaščito proti ošpicam, mumpsu in rdečkam).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="6"> |
|
<prop type="lengthRatio">1.013953488372093</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It means that people who cannot be vaccinated, for instance because they are too young or allergic to vaccine components, benefit from others being vaccinated, because the disease cannot easily spread in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>To pomeni, da imajo ljudje, ki ne morejo biti cepljeni, na primer zaradi tega, ker so premladi ali alergični na sestavine v cepivu, koristi od cepljenja drugih ljudi, saj se s tem omeji širjenje bolezni v skupnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="7"> |
|
<prop type="lengthRatio">0.877906976744186</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Sem spadajo dojenčki, otroci, starostniki, osebe z oslabelim imunskim sistemom, bolniki z rakavimi obolenji in ljudje, pri katerih iz medicinskih razlogov ni mogoče cepiti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="8"> |
|
<prop type="lengthRatio">0.8571428571428571</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva na ta način posredno ščitijo tudi druge ljudi, ki so dovzetnejši za zadevno bolezen.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="9"> |
|
<prop type="lengthRatio">1.064</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When enough people in a population are immune to an infectious disease, the disease is then unlikely to spread from person to person.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če je v populaciji dovolj ljudi imunih za določeno nalezljivo bolezen, je manj verjetno, da se bo ta širila z osebe na osebo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="10"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kolektivna imunost se vzpostavi, kadar je dovolj ljudi v populaciji imunih na nalezljivo bolezen</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="11"> |
|
<prop type="lengthRatio">0.9213483146067416</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje ne ščiti le posameznika, ki je prejel cepivo, temveč tudi ljudi v njegovi okolici, ki so dovzetnejši za nalezljive bolezni, saj se s cepljenjem zmanjša tveganje širjenja bolezni med člani družine, sošolci, prijatelji, sosedi in drugimi pripadniki skupnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="12"> |
|
<prop type="lengthRatio">0.9518072289156626</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Toda pri nekaterih nalezljivih boleznih se ni mogoče zanesti na kolektivno imunost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="13"> |
|
<prop type="lengthRatio">1.1333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When to vaccinate</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdaj se cepiti?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="14"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S cepljenjem zaščitimo posameznike pred boleznimi, ki bi lahko imele resne posledice za njihovo zdravje:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="15"> |
|
<prop type="lengthRatio">0.9769230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>pertusis (oslovski kašelj) je lahko zlasti nevaren pri dojenčkih, saj povzroča napade kašlja, ki lahko trajajo tudi do dva meseca.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="16"> |
|
<prop type="lengthRatio">0.8771929824561403</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na tem seznamu so navedeni primeri bolezni, proti katerim se je mogoče cepiti v okviru nacionalnih programov imunizacije oziroma pri katerih je cepljenje priporočljivo za osebe, pri katerih obstaja visoko tveganje za obolevnost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="17"> |
|
<prop type="lengthRatio">1.0310880829015545</prop> |
|
<tuv xml:lang="en"> |
|
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>skoraj devet od desetih dojenčkov, katerih matere so v zgodnji nosečnosti prebolele rdečke, bo imelo sindrom prirojenih rdečk (za katerega so značilni gluhost, katarakta in duševne motnje) (2);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="18"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med zapleti so lahko pljučnica, encefalopatija (okvara možganov), epileptični napadi in celo smrt (5).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="19"> |
|
<prop type="lengthRatio">1.0264550264550265</prop> |
|
<tuv xml:lang="en"> |
|
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>ošpice so izredno nalezljive, pri treh okuženih osebah od desetih pa se pojavijo zapleti (4), ki lahko vključujejo vnetje ušesa, drisko, pljučnico in encefalitis (vnetje možganskega tkiva);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="20"> |
|
<prop type="lengthRatio">0.762962962962963</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje ne ščiti le posameznika, ki je prejel cepivo, temveč tudi ljudi v njegovi okolici, ki so dovzetnejši za nalezljive bolezni...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="21"> |
|
<prop type="lengthRatio">0.9716981132075472</prop> |
|
<tuv xml:lang="en"> |
|
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>kljub pravočasni diagnozi in zdravljenju zaradi meningokokne bolezni umre vsaka deseta obolela oseba, medtem ko se lahko pri 20 % preživelih oseb pojavijo še nevrološke okvare, težave s sluhom ali amputacija (3);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="22"> |
|
<prop type="lengthRatio">0.6666666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(4) US CDC Pink Book - Measles: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>(4) Roza knjižica ministrstva ZDA za zdravje in socialne zadeve - Rdečke: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="23"> |
|
<prop type="lengthRatio">1.088235294117647</prop> |
|
<tuv xml:lang="en"> |
|
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>kljub zdravljenju zaradi davice umre vsaka deseta okužena oseba (1);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="24"> |
|
<prop type="lengthRatio">0.9375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(3) ECDC factsheet - Meningococcal disease: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>(3) Informativni list ECDC - Meningokokna bolezen: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="25"> |
|
<prop type="lengthRatio">0.9576271186440678</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>(2) Informativni list ECDC - Sindrom prirojenih rdečk: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="26"> |
|
<prop type="lengthRatio">0.8461538461538461</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>(5) Informativni list ECDC - Oslovski kašelj: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="27"> |
|
<prop type="lengthRatio">0.9666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Safety, quality and standards</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Varnost, kakovost in standardi</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="28"> |
|
<prop type="lengthRatio">1.2131147540983607</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prvo cepivo so razvili v 18. stoletju v Združenem kraljestvu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="29"> |
|
<prop type="lengthRatio">0.9722222222222222</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Serious side effects are very rare.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Resni neželeni učinki so zelo redki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="30"> |
|
<prop type="lengthRatio">0.8888888888888888</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zadnja znana naravna epidemija črnih koz je bila zabeležena v Somaliji leta 1977.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="31"> |
|
<prop type="lengthRatio">0.9850746268656716</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They also help to prevent the spread of diseases in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Hkrati pa pripomorejo k preprečevanju širjenja bolezni v skupnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="32"> |
|
<prop type="lengthRatio">0.9812206572769953</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za uporabo v Evropski uniji (EU) in Evropskem gospodarskem prostoru (EGP) se cepivo lahko odobri samo na podlagi znanstvene ocene rezultatov teh preizkušanj, kar jamči za njegovo kakovost, varnost in učinkovitost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="33"> |
|
<prop type="lengthRatio">0.8952380952380953</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Šele potem, ko je cepivo odobreno, se ga lahko začne proizvajati, tržiti in uporabljati za zaščito ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="34"> |
|
<prop type="lengthRatio">0.9941860465116279</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Znanstveni strokovnjaki, ki ocenjujejo cepiva, vselej zelo skrbno pretehtajo koristi in morebitna tveganja cepiv, zlasti zaradi tega, ker se uporabljajo pri zdravih ljudeh.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="35"> |
|
<prop type="lengthRatio">1.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccinating</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dejstva o cepivih</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="36"> |
|
<prop type="lengthRatio">0.8175675675675675</prop> |
|
<tuv xml:lang="en"> |
|
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kot to velja za katero koli zdravilo, se lahko pri nekaterih ljudeh pojavijo neželeni učinki cepljenja, vendar so ti običajno blagi in kratkotrajni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="37"> |
|
<prop type="lengthRatio">0.8068181818181818</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before any new vaccine can be used, it has to undergo rigorous testing.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Preden se novo cepivo lahko začne uporabljati, mora prestati zelo zahtevna preizkušanja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="38"> |
|
<prop type="lengthRatio">0.6373626373626373</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They mainly target diseases caused by viruses or bacteria.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V glavnem se uporabljajo za zaščito pred boleznimi, ki jih povzročajo virusi ali bakterije.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="39"> |
|
<prop type="lengthRatio">0.8863636363636364</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva so neprestano pod skrbnim nadzorom, da se ohrani njihova varnost in učinkovitost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="40"> |
|
<prop type="lengthRatio">1.0307692307692307</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ta ocena mora pokazati, da so koristi cepiva pri zaščiti ljudi pred boleznimi mnogo večje od morebitnih tveganj, povezanih z njim.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="41"> |
|
<prop type="lengthRatio">0.9316239316239316</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are used worldwide as a highly effective way to protect people from contracting infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva se uporabljajo po vsem svetu kot zelo učinkovita metoda za zaščito ljudi pred okužbo z nalezljivimi boleznimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="42"> |
|
<prop type="lengthRatio">0.9844961240310077</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo", kako naj se brani pred določeno boleznijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="43"> |
|
<prop type="lengthRatio">0.7368421052631579</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They can include mild fever, or pain or redness at the injection site.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vključujejo blago povišanje telesne temperature ali bolečino in pordelost na mestu injiciranja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="44"> |
|
<prop type="lengthRatio">1.0769230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nedavno je bilo razvito cepivo proti virusu ebole, v teku pa je tudi razvoj cepiva proti okužbi z virusom humane imunske pomanjkljivosti (HIV).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="45"> |
|
<prop type="lengthRatio">0.5777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It was a vaccine against smallpox, a deadly disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Namenjeno je bilo cepljenju proti črnim kozam, za katere je bila značilna visoka smrtnost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="46"> |
|
<prop type="lengthRatio">0.8518518518518519</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zahvaljujoč cepljenju so črne koze pri ljudeh danes izkoreninjene po celem svetu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="47"> |
|
<prop type="lengthRatio">0.496</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Research is ongoing to develop vaccines against more diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Danes imamo na voljo cepiva za številne bolezni, raziskave za razvoj novih cepiv proti mnogim drugim boleznim pa še potekajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="48"> |
|
<prop type="lengthRatio">0.8695652173913043</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most vaccines provide lifelong immunity.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Večina cepiv zagotavlja doživljenjsko imunost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="49"> |
|
<prop type="lengthRatio">0.9861111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za določene bolezni se lahko organizirajo programi naknadnega cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="50"> |
|
<prop type="lengthRatio">1.036144578313253</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kadar posameznik ne ve, ali je bil cepljen proti določeni bolezni, lahko običajno prejme dodaten odmerek ustreznega cepiva brez tveganja za resne neželene učinke (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="51"> |
|
<prop type="lengthRatio">0.8616352201257862</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zaradi naraščajočega števila primerov ošpic med najstniki in mladimi odraslimi so bili na primer v številnih državah EU/EGP organizirani programi naknadnega cepljenja za ljudi, ki so morda zamudili cepljenje proti ošpicam v otroštvu ali pa so prestari, da bi lahko bili v otroštvu vključeni v takšen program cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="52"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Catch-up vaccination and boosters</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Naknadno in obnovitveno cepljenje</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="53"> |
|
<prop type="lengthRatio">0.8409090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsak posameznik mora preveriti, ali je prejel vsa cepiva, ki so priporočena v njegovi državi, in se v primeru, da mora določena cepljenja še opraviti, posvetovati z zdravnikom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="54"> |
|
<prop type="lengthRatio">0.9117647058823529</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med njimi pa so tudi takšna, pri katerih se imunost sčasoma zmanjša, čemur rečemo „zmanjšana imunost".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="55"> |
|
<prop type="lengthRatio">0.9173553719008265</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ti podatki se lahko razberejo iz cepilne knjižice ali koledarja cepljenja, ki je bil veljaven v času rojstva posameznika.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="56"> |
|
<prop type="lengthRatio">1.084033613445378</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za nekatere bolezni, kot so norice in rdečke, je na voljo testiranje, ki pokaže ali je oseba imuna za omenjeni bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="57"> |
|
<prop type="lengthRatio">0.6953125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Osebe, ki so morda zamudile določeno cepljenje ali pa niso prejele vseh priporočenih odmerkov, se lahko še vednonaknadno cepijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="58"> |
|
<prop type="lengthRatio">1.5963302752293578</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere države priporočajo, da se mladostniki in odrasli v rednih presledkih cepijo z obnovitvenimi odmerki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="59"> |
|
<prop type="lengthRatio">0.9078947368421053</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is offered to women in accordance with national recommendations.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tovrstna testiranja so ženskam na voljo v skladu z nacionalnimi priporočili.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="60"> |
|
<prop type="lengthRatio">0.9375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za več informacij si oglejte spletišče centra ECDC: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="61"> |
|
<prop type="lengthRatio">1.2115384615384615</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is the most common sexually transmitted infection worldwide.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Je najpogostejša spolno prenosljiva okužba na svetu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="62"> |
|
<prop type="lengthRatio">1.118421052631579</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The use of condoms is not 100% effective in preventing the transmission of the virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Uporaba kondoma pri preprečevanju prenosa virusa ni 100-odstotno učinkovita.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="63"> |
|
<prop type="lengthRatio">0.7872340425531915</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If HPV does not go away it may cause:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če se okužba s HPV ne pozdravi, lahko povzroči:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="64"> |
|
<prop type="lengthRatio">1.0714285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Genital warts can be treated using medication or by surgery.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Genitalne bradavice se zdravijo z zdravili ali kirurško.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="65"> |
|
<prop type="lengthRatio">1.0406504065040652</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Rutinsko cepljenje proti okužbi s HPV poteka načeloma v starosti od 9 do 14 let v skladu z nacionalnim programom cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="66"> |
|
<prop type="lengthRatio">0.9745762711864406</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, sometimes the HPV infection can persist and cause after some years some of the complications listed below.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nekaterih primerih pa lahko okužba s HPV vztraja in povzroči tudi po več letih katerega od spodaj naštetih zapletov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="67"> |
|
<prop type="lengthRatio">1.5692307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is because HPV can also occasionally infect surrounding skin that is not protected by the condom.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>HPV lahko namreč okuži tudi okoliško kožo, ki je kondom ne ščiti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="68"> |
|
<prop type="lengthRatio">1.2117647058823529</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In most cases, an HPV infection disappears on its own without causing any obvious symptoms or problems.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V večini primerov okužba s HPV izzveni samodejno brez očitnejših simptomov ali težav.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="69"> |
|
<prop type="lengthRatio">1.2347826086956522</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Rak materničnega vratu je za rakom dojk najpogostejši rak, ki prizadene ženske v starosti od 14 do 44 let v Evropi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="70"> |
|
<prop type="lengthRatio">0.7068965517241379</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 40 of them can infect the genitals.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med njimi je okoli 40 takšnih, ki lahko okužijo spolovila.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="71"> |
|
<prop type="lengthRatio">1.40625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There are more than 100 types of HPV viruses.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Virusov HPV je več kot 100 vrst.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="72"> |
|
<prop type="lengthRatio">1.0793650793650793</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Okužba s humanim papiloma virusom (HPV) je virusna okužba, ki se prenaša večinoma spolno z neposrednim stikom z okuženo osebo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="73"> |
|
<prop type="lengthRatio">1.0909090909090908</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kaj je HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="74"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka oseba, ki je spolno dejavna, tvega okužbo s HPV.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="75"> |
|
<prop type="lengthRatio">1.0648148148148149</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za sam virus ni zdravila, obstajajo pa različni načini zdravljenja bolezenskih stanj, ki jih virus povzroča.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="76"> |
|
<prop type="lengthRatio">0.8529411764705882</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V zvezi z različnimi možnostmi zdravljenja se je treba posvetovati s izvajalci zdravstvene dejavnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="77"> |
|
<prop type="lengthRatio">0.9026548672566371</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje fantov in deklet lahko prepreči okužbo s HPV in posledično bolezni, povezane s temi virusi pri obeh spolih, med drugim genitalne in analne bradavice, raka materničnega vratu in druge vrste rakov, ki jih povzroča HPV.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="78"> |
|
<prop type="lengthRatio">0.7671232876712328</prop> |
|
<tuv xml:lang="en"> |
|
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>raka materničnega vratu ali druge vrste raka (npr.: vulve in nožnice, raka analnega kanala, raka na penisu ter nekatere vrste raka glave in vratu)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="79"> |
|
<prop type="lengthRatio">0.8145161290322581</prop> |
|
<tuv xml:lang="en"> |
|
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaj 14 vrst virusa HPV je visoko rizičnih in lahko povzročijo nastanek raka, na primer raka materničnega vratu pri ženskah.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="80"> |
|
<prop type="lengthRatio">0.7586206896551724</prop> |
|
<tuv xml:lang="en"> |
|
<seg>genital and anal warts</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>genitalne in analne bradavice</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="81"> |
|
<prop type="lengthRatio">0.810126582278481</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Visoko rizični tipi virusov HPV lahko povzročijo tudi raka analnega kanala in spolovil ter nekatere vrste raka vratu in glave tako pri moških kot pri ženskah.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="82"> |
|
<prop type="lengthRatio">0.7435897435897436</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nizko rizični tipi virusov HPV lahko povzročijo genitalne in analne bradavice.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="83"> |
|
<prop type="lengthRatio">0.4888888888888889</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdo je izpostavljen tveganju za okužbo s HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="84"> |
|
<prop type="lengthRatio">0.90625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so simptomi okužbe s HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="85"> |
|
<prop type="lengthRatio">1.2672413793103448</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Raka materničnega vratu in predrakave spremembe v materničnem tkivu se s testiranjem lahko zgodaj odkrije in zdravi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="86"> |
|
<prop type="lengthRatio">0.9545454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Virusi HPV se širijo z neposrednim stikom z okuženo osebo, največkrat s spolnimi odnosi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="87"> |
|
<prop type="lengthRatio">1.247787610619469</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tudi druge vrste rakov, ki so povezani z okužbo s HPV, so ozdravljive, če se jih odkrije in zdravi dovolj zgodaj.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="88"> |
|
<prop type="lengthRatio">1.096774193548387</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of HPV?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe s HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="89"> |
|
<prop type="lengthRatio">0.6944444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can HPV be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se zaščititi pred okužbo s HPV?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="90"> |
|
<prop type="lengthRatio">0.6785714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is HPV treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se okužba s HPV zdravi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="91"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>non-productive cough.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>neproduktiven kašelj.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="92"> |
|
<prop type="lengthRatio">1.1020408163265305</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Children are infected slightly more often than adults.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Otroci se okužijo nekoliko pogosteje kot odrasli.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="93"> |
|
<prop type="lengthRatio">0.9647058823529412</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is also spread via secretions on hands, tissues and surfaces that people touch.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prenaša se tudi z izločki na dlaneh, robčkih in površinah, ki se jih ljudje dotikajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="94"> |
|
<prop type="lengthRatio">0.927710843373494</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These epidemics are associated with high hospitalisation rates and mortality.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Te epidemije so povezane z visokimi stopnjami hospitalizacije in visoko smrtnostjo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="95"> |
|
<prop type="lengthRatio">0.8606060606060606</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pandemija gripe A(H1N1)pdm09 leta 2009 je po svetu povzročila od 123 000 do 203 000 smrtnih primerov in je pomenila pomembno svetovno družbeno‑gospodarsko breme (3).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="96"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The World Health Organization (WHO) also recommends vaccination for healthcare workers.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Svetovna zdravstvena organizacija (SZO) cepljenje priporoča tudi zdravstvenim delavcem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="97"> |
|
<prop type="lengthRatio">1.065359477124183</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Večina držav članic EU upošteva priporočila SZO glede cepljenja nosečnic, nekatere upoštevajo priporočila o cepljenju zdravih otrok, starih 6-59 mesecev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="98"> |
|
<prop type="lengthRatio">1.0188679245283019</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza is easily transmitted from person to person.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Gripa se zlahka prenaša s posameznika na posameznika.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="99"> |
|
<prop type="lengthRatio">0.9746835443037974</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V Evropi se gripa pojavlja v obliki rednih vsakoletnih epidemij v zimskem času.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="100"> |
|
<prop type="lengthRatio">1.136</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The EU Council Recommendation on seasonal influenza vaccination encourages countries to improve vaccination coverage among healthcare workers.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Priporočilo Sveta EU o cepljenju proti sezonski gripi spodbuja države k izboljšanju precepljenosti med zdravstvenimi delavci.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="101"> |
|
<prop type="lengthRatio">1.106060606060606</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pandemija je hitro širjenje novega virusa človeške gripe po svetu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="102"> |
|
<prop type="lengthRatio">1.2835820895522387</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Patients are advised to seek medical advice if their condition continues to get worse.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Bolniki naj se z zdravnikom posvetujejo, če se jim stanje poslabša.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="103"> |
|
<prop type="lengthRatio">1.164021164021164</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Po ocenah je bila smrtnost zaradi gripe v državah EU/EGP, ki sodelujejo v mreži EuroMOMO (1), med sezono gripe v letih 2016/17 in 2017/18 kar 25 smrtnih primerov na 100 000 prebivalcev (2).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="104"> |
|
<prop type="lengthRatio">0.9052631578947369</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, antivirals are generally recommended for severe or rapidly progressing cases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na splošno pa priporočajo uporabo tovrstnih zdravil le v hudih ali hitro napredujočih primerih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="105"> |
|
<prop type="lengthRatio">1.084033613445378</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsako leto se z gripo okuži približno 20 % prebivalstva, znaki okužbe pa se pojavijo pri enem od štirih okuženih ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="106"> |
|
<prop type="lengthRatio">0.8981818181818182</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Države članice EU priporočajo cepljenje proti sezonski gripi za skupine ljudi z večjim tveganjem, kot so starejši, ter za osebe s kroničnimi bolezenskimi stanji, kot so srčno‑žilna bolezen, težave s pljuči in dihalnimi potmi, sladkorna bolezen ali težave z imunskim sistemom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="107"> |
|
<prop type="lengthRatio">0.7672955974842768</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Huda bolezen in zapleti so pogostejši pri zelo majhnih dojenčkih, starejših ljudeh šibkega zdravja in določenih skupinah prebivalstva z zdravstvenim tveganjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="108"> |
|
<prop type="lengthRatio">1.0618556701030928</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Poleg sezonskih epidemij se občasno lahko pojavijo novi virusi influence in povzročijo pandemijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="109"> |
|
<prop type="lengthRatio">1.1891891891891893</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Animals can also be infected with influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Z gripo se lahko okužijo tudi živali.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="110"> |
|
<prop type="lengthRatio">1.1005917159763314</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza pandemics happen when a new strain of a flu virus appears which can infect humans, to which most people have no immunity and which can transmit efficiently from human to human.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Do pandemije gripe pride, ko se pojavi nov sev virusa influence, ki lahko okuži ljudi in proti kateremu večina ljudi ni imuna ter se lahko učinkovito prenaša med ljudmi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="111"> |
|
<prop type="lengthRatio">1.0338983050847457</prop> |
|
<tuv xml:lang="en"> |
|
<seg>People with pre-existing medical conditions are at higher risk of their condition worsening following influenza infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri ljudeh z obstoječimi bolezenskimi stanji obstaja večje tveganje, da se njihovo stanje poslabša po okužbi z gripo .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="112"> |
|
<prop type="lengthRatio">1.1232876712328768</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nezapletenih primerih znaki izzvenijo samodejno v enem tednu od pojava.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="113"> |
|
<prop type="lengthRatio">1.2523364485981308</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antiviral medicines, taken as rapidly as possible after illness onset, are safe and effective measures for the treatment of influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če protivirusna zdravila vzamemo čim prej po začetku bolezni, so pri zdravljenju gripe varna in učinkovita.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="114"> |
|
<prop type="lengthRatio">0.9711538461538461</prop> |
|
<tuv xml:lang="en"> |
|
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva za sezonsko gripo je treba vsako leto na novo pripraviti, saj se virusi gripe stalno spreminjajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="115"> |
|
<prop type="lengthRatio">0.8571428571428571</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases, humans can be infected by animals, such as in cases of avian and swine influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nekaterih primerih se lahko ljudje okužijo od živali; to se je na primer zgodilo pri ptičji in prašičji gripi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="116"> |
|
<prop type="lengthRatio">0.9792746113989638</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V večini primerov okužbe z gripo se bolnikom za lajšanje simptomov svetujeta počitek in pitje zadostne količine tekočine; z zadrževanjem doma se tudi zmanjša tveganje za prenos okužbe na druge.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="117"> |
|
<prop type="lengthRatio">1.016260162601626</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nekaterih primerih pri bolnikih po okužbi z gripo pride do bakterijskih zapletov, ki jih je treba zdraviti z antibiotiki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="118"> |
|
<prop type="lengthRatio">1.1047120418848169</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dajanje protivirusnih zdravil je poleg cepljenja tudi varen in učinkovit ukrep za zaščito pred okužbo z gripo ali za zmanjšanje resnosti okužbe v določenih okoljih, kot so domovi za starejše.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="119"> |
|
<prop type="lengthRatio">1.2467532467532467</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Gripa je nalezljiva bolezen dihal, ki jo povzroča okužba z virusom influence.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="120"> |
|
<prop type="lengthRatio">1.446808510638298</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsi, ki se okužijo z virusom gripe, ne zbolijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="121"> |
|
<prop type="lengthRatio">0.9044585987261147</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prenos v glavnem poteka prek neposrednega stika z izločki kužnih bolnikov, kot so kapljice tekočine, ki se izločajo med njihovim kašljanjem ali izdihavanjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="122"> |
|
<prop type="lengthRatio">0.7417582417582418</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Even so, about half of the children and working-age adults needing admission to intensive care have no pre-existing medical conditions.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kljub temu približno polovica otrok in delovno sposobnih odraslih, ki potrebujejo oskrbo na oddelku intenzivno nego zaradi zapletov okužbe z gripo, nima predhodnih bolezenskih stanj.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="123"> |
|
<prop type="lengthRatio">1.303030303030303</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For those that do, common symptoms include:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pogosti znaki pri obolelih pa so:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="124"> |
|
<prop type="lengthRatio">0.9230769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>sore throat;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>boleče žrelo;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="125"> |
|
<prop type="lengthRatio">0.8805970149253731</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the most effective way to prevent influenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Najučinkovitejši način za zaščito pred okužbo z gripo je cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="126"> |
|
<prop type="lengthRatio">0.5957446808510638</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdo je izpostavljen tveganju za okužbo z gripo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="127"> |
|
<prop type="lengthRatio">0.7560975609756098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Resnost bolezni se zelo razlikuje, oboleli morda sploh nimajo znakov okužbe ali pa se pri njih razvije huda oblika bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="128"> |
|
<prop type="lengthRatio">1.1842105263157894</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Možna zapleta okužbe z gripo sta pljučnica in encefalitis (vnetje možganov).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="129"> |
|
<prop type="lengthRatio">1.0909090909090908</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is influenza spread?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se gripa prenaša?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="130"> |
|
<prop type="lengthRatio">1.2121212121212122</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe z gripo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="131"> |
|
<prop type="lengthRatio">1.1290322580645162</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so znaki okužbe z gripo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="132"> |
|
<prop type="lengthRatio">0.8157894736842105</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can influenza be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se zaščititi pred okužbo z gripo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="133"> |
|
<prop type="lengthRatio">0.8333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How is influenza treated?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se okužba z gripo zdravi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="134"> |
|
<prop type="lengthRatio">1.565217391304348</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Clinical Microbiology and Infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>vročina ali vročičnost;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="135"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1-4 people</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>1-4 osebe</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="136"> |
|
<prop type="lengthRatio">1.064516129032258</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Fifth Edition 2008, Elsevier Inc.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Peta izdaja 2008, Elsevier Inc.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="137"> |
|
<prop type="lengthRatio">1.0833333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination programmes have wider societal benefits.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Programi cepljenja imajo širše družbene koristi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="138"> |
|
<prop type="lengthRatio">0.9761904761904762</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Slika prikazuje tako konzervativno oceno (notranji krog, temnejše pike) kot tudi najvišjo oceno (zunanji krog, bledejše pike).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="139"> |
|
<prop type="lengthRatio">0.7708333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>smallpox is now eradicated worldwide;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>so črne koze sedaj izkoreninjene po celem svetu;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="140"> |
|
<prop type="lengthRatio">1.0862068965517242</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination helps prevent the spread of disease in communities.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje pomaga preprečiti širjenje bolezni v skupnostih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="141"> |
|
<prop type="lengthRatio">0.875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>transmission of polio has ended in most parts of the world, including Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>se je širjenje virusa otroške paralize ustavilo v večini delov sveta, vključno z Evropo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="142"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The centre dot represent one person affected by a disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pika v sredini predstavlja eno osebo, okuženo z boleznijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="143"> |
|
<prop type="lengthRatio">1.28</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če je cepljen velik delež prebivalstva, se nalezljive bolezni težje širijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="144"> |
|
<prop type="lengthRatio">1.1122448979591837</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje istočasno preprečuje nastanek določenih vrst predrakavih in rakavih sprememb, na primer:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="145"> |
|
<prop type="lengthRatio">1.4529411764705882</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zmanjšujejo tudi pritisk na sisteme zdravstvenega in socialnega varstva in omogočajo ljudem udejstvovanje v produktivnih dejavnostih, kot sta izobraževanje in zaposlitev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="146"> |
|
<prop type="lengthRatio">0.9580838323353293</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pike, povezane s sredinsko piko, predstavljajo največje in najmanjše število predhodno neokuženih in necepljenih oseb, ki bi se lahko okužile ob stiku z obolelo osebo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="147"> |
|
<prop type="lengthRatio">0.8524590163934426</prop> |
|
<tuv xml:lang="en"> |
|
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>cepljenje proti hepatitisu B lahko pomaga preprečiti raka jeter, ki ga povzroča dolgotrajna okužba z virusom hepatitisa B.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="148"> |
|
<prop type="lengthRatio">0.7382198952879581</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination is the best way to acquire immunity against vaccine-preventable diseases, as opposed to immunity attained by getting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje je najboljši način za vzpostavitev imunosti proti boleznim, ki jih je mogoče preprečiti s cepljenjem, za razliko od naravne imunosti, ki se vzpostavi s prebolenjem določene bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="149"> |
|
<prop type="lengthRatio">0.756578947368421</prop> |
|
<tuv xml:lang="en"> |
|
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>cepljenje proti humanemu papilomavirusu (HPV) lahko pomaga preprečiti raka materničnega vratu in druge vrste raka, ki jih povzroča okužba z virusom HPV;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="150"> |
|
<prop type="lengthRatio">1.0975609756097562</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination prevents people from getting the symptoms of the disease, which can be severe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje lahko prepreči nastanek simptomov bolezni, ki so lahko včasih zelo hudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="151"> |
|
<prop type="lengthRatio">0.5060975609756098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Temu rečemo „kolektivna imunost" (z drugo besedo tudi „čredna imunost").S cepljenjem lahko bolezni izkoreninimo ali znatno zmanjšamo število novih primerov bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="152"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In Europe, influenza occurs...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V Evropi se gripa pojavlja…</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="153"> |
|
<prop type="lengthRatio">1.0208333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Preden se cepivo lahko odobri v EU, mora prestati zelo zahtevna preskušanja razvijalca cepiva...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="154"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines protect people during different stages of life.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva varujejo ljudi v različnih življenjskih obdobjih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="155"> |
|
<prop type="lengthRatio">1.0333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S cepljenjem zaščitimo posameznike pred boleznimi, ki bi lahko imele resne posledice za...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="156"> |
|
<prop type="lengthRatio">0.9457364341085271</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsak virus ali bakterija sproži enkraten odziv imunskega sistema, pri čemer igrajo pomembno vlogo posebne skupine celic v krvi...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="157"> |
|
<prop type="lengthRatio">1.3125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Approval of vaccines in the European Union</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Odobritev cepiv v Evropski uniji</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="158"> |
|
<prop type="lengthRatio">1.3928571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Vaccination Information Portal</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropski portal za cepljenje</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="159"> |
|
<prop type="lengthRatio">0.85</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How vaccines work</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako cepiva delujejo</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="160"> |
|
<prop type="lengthRatio">1.0363636363636364</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Okužba s humanim papiloma virusom (HPV) je virusna okužba, ki se večinoma spolno prenaša z neposrednim stikom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="161"> |
|
<prop type="lengthRatio">0.8181818181818182</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are recommended for different age...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva so priporočljiva za različne starostne skupine..</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="162"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Trusted sources</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="163"> |
|
<prop type="lengthRatio">2.1666666666666665</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for individuals</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Učinkovitost cepiv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="164"> |
|
<prop type="lengthRatio">1.1630434782608696</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj je zelo nalezljiva bakterijska bolezen, ki prizadene pljuča in dihalne poti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="165"> |
|
<prop type="lengthRatio">1.0789473684210527</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This ensures that any possible risks are detected and managed as soon as possible.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S tem se zagotovi, da se morebitna tveganja odkrijejo in obvladajo čim prej.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="166"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It analyses many sources of data, including:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Analizira številne vire podatkov,, in sicer:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="167"> |
|
<prop type="lengthRatio">1.04</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za več informacij glejte:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="168"> |
|
<prop type="lengthRatio">1.1538461538461537</prop> |
|
<tuv xml:lang="en"> |
|
<seg>reports from patients, parents and healthcare professionals;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>poročila bolnikov, staršev in zdravstvenih delavcev;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="169"> |
|
<prop type="lengthRatio">0.7090909090909091</prop> |
|
<tuv xml:lang="en"> |
|
<seg>information shared by other regulators.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>informacije, ki jih sporočijo drugi regulativni organi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="170"> |
|
<prop type="lengthRatio">0.8953488372093024</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA preverja nove informacije o varnosti vseh cepiv, ki so na voljo v Evropi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="171"> |
|
<prop type="lengthRatio">1.1195652173913044</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Postopek spremljanja varnosti in obvladovanja tveganj zdravil se imenuje „farmakovigilanca".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="172"> |
|
<prop type="lengthRatio">0.84</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When needed, EMA and the other European regulators take action.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA in drugi evropski regulativni organi po potrebi tudi ukrepajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="173"> |
|
<prop type="lengthRatio">0.9402985074626866</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, they can provide updated guidance to healthcare workers, or even restrict the use of a vaccine in certain groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tako lahko na primer izdajo posodobljena navodila za zdravstvene delavce ali celo omejijo uporabo cepiva pri določenih skupinah ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="174"> |
|
<prop type="lengthRatio">1.0853658536585367</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ko je cepivo odobreno za uporabo, nacionalni organi EU/EGP in Evropska agencija za zdravila (EMA) stalno spremljajo neželene učinke pri ljudeh, ki so bili cepljeni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="175"> |
|
<prop type="lengthRatio">1.0483870967741935</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tako lahko izključi možnost, da gre za naključje ali da so jih povzročili drugi dejavniki, ki niso povezani s samim cepivom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="176"> |
|
<prop type="lengthRatio">0.8790322580645161</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA skrbno ovrednoti domnevne neželene učinke zdravil, da ugotovi, ali obstaja vzročna povezava med cepivom ali ne.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="177"> |
|
<prop type="lengthRatio">0.8666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Monitoring vaccine safety and reporting side effects</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Spremljanje varnosti cepiva in poročanje o neželenih učinkih</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="178"> |
|
<prop type="lengthRatio">0.9447852760736196</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Bolniki, zdravstveni delavci in farmacevtska podjetja morajo svojim nacionalnim regulativnim organom za zdravila poročati o vseh domnevnih neželenih učinkih cepiv.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="179"> |
|
<prop type="lengthRatio">0.84375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij o tem, kako poročati o domnevnih neželenih učinkih, je mogoče najti v informacijah o predpisovanju zdravil, navodilih za uporabo ali v evropski podatkovni zbirki poročil o domnevnih neželenih učinkih zdravil .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="180"> |
|
<prop type="lengthRatio">0.9664429530201343</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Informacije o prijavljenih domnevnih neželenih učinkih so javno dostopne v evropski podatkovni zbirki poročil o domnevnih neželenih učinkih zdravil .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="181"> |
|
<prop type="lengthRatio">1.0138888888888888</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These could be due to an illness or anxiety over being given the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ti dejavniki vključujejo že obstoječo bolezen ali strah pred cepljenjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="182"> |
|
<prop type="lengthRatio">0.625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More factsheets</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informativnih listov</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="183"> |
|
<prop type="lengthRatio">0.9347826086956522</prop> |
|
<tuv xml:lang="en"> |
|
<seg>the eyes become red and sensitive to light;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>oči postanejo rdeče in občutljive za svetlobo;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="184"> |
|
<prop type="lengthRatio">0.9074074074074074</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij je na voljo na spletišču centra ECDC: https://www.ecdc.europa.eu/en/measles/facts/factsheet .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="185"> |
|
<prop type="lengthRatio">0.9305555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>med tretjim in sedmim dnem se lahko telesna temperatura poveča do 41 ⁰C;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="186"> |
|
<prop type="lengthRatio">1.118279569892473</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ocenjuje se, da lahko ena oseba z ošpicami v povprečju okuži med 12 in 18 nezaščitenih ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="187"> |
|
<prop type="lengthRatio">1.2285714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no specific treatment for measles.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Posebnega zdravljenja za ošpice ni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="188"> |
|
<prop type="lengthRatio">1.1475409836065573</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is a serious disease that can lead to complications and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Gre za resno bolezen, ki lahko povzroči zaplete in celo smrt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="189"> |
|
<prop type="lengthRatio">1.3076923076923077</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against measles is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Edina zaščita pred okužbo je cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="190"> |
|
<prop type="lengthRatio">1.2323232323232323</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Drugi odmerek se daje en mesec ali več po prvem odmerku v skladu z nacionalnim programom cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="191"> |
|
<prop type="lengthRatio">0.975</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first dose is given between 10 and 18 months of age in European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prvi odmerek se v evropskih državah daje, ko je otrok star od 10 do 18 mesecev .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="192"> |
|
<prop type="lengthRatio">1.367741935483871</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Opomba: Informacije, podane v tem informativnem listu, so zgolj splošne narave in nikakor ne nadomeščajo zdravnikove strokovne presoje posameznega primera.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="193"> |
|
<prop type="lengthRatio">0.9405940594059405</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>na obrazu se pojavi rdeč izpuščaj, ki traja od štiri do sedem dni in se nato razširi po celem telesu;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="194"> |
|
<prop type="lengthRatio">1.0331491712707181</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Infants from six to nine months of age who are in an area - or will be travelling to areas - with high risk of exposure to measles, should receive a supplementary dose of the MMR vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dojenčki, ki so stari od šest do devet mesecev in so na območju ali bodo potovali na območja z visokim tveganjem izpostavljenosti ošpicam, morajo prejeti dodatni odmerek cepiva OMR.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="195"> |
|
<prop type="lengthRatio">0.9938650306748467</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Such dose before the age of nine months is supplementary to the two doses included in the national vaccination programme, which are aimed to give full protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ta odmerek pred dopolnjenim devetim mesecem dopolnjuje druga dva odmerka, ki sta del nacionalnega programa cepljenja, katerega namen je zagotoviti popolno zaščito.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="196"> |
|
<prop type="lengthRatio">1.1818181818181819</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Antibiotiki proti ošpicam niso učinkoviti, saj jih povzroča virus.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="197"> |
|
<prop type="lengthRatio">1.2100840336134453</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kapljice, ki vsebujejo virus, lahko v zraku ostanejo več ur, virus pa ostane na okuženih površinah kužen še do dve uri.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="198"> |
|
<prop type="lengthRatio">1.0416666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>30% of children and adults infected with measles can develop complications.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Do zapletov lahko pride pri 30 % otrok in odraslih, okuženih z ošpicami.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="199"> |
|
<prop type="lengthRatio">0.9349593495934959</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Znaki te bolezni so spremembe osebnosti, postopno poslabšanje duševnega stanja, mišični krči in drugi živčno-mišični znaki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="200"> |
|
<prop type="lengthRatio">1.1346153846153846</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Two doses of the vaccine are needed for maximum protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za optimalno zaščito zadostujeta dva odmerka cepiva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="201"> |
|
<prop type="lengthRatio">1.2592592592592593</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Je varno in učinkovito ter ima malo neželenih učinkov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="202"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There is no cure for SSPE and it always leads to death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za to bolezen zdravilo ne obstaja in vedno vodi v smrt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="203"> |
|
<prop type="lengthRatio">0.9769230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zelo redko lahko trajna okužba z virusom ošpic povzroči subakutni sklerozirajoči panencefalitis (SSPE), bolezen, pri kateri živci in možgansko tkivo postopoma degenerirajo in za katero obstaja večja verjetnost, da se pojavi, če do okužbe pride v mlajših letih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="204"> |
|
<prop type="lengthRatio">0.9140625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri vsaki osebi, ki ni bila cepljena proti ošpicam ali jih ni prebolela, obstaja tveganje, da se okuži pri kateri koli starosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="205"> |
|
<prop type="lengthRatio">0.9538461538461539</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Znaki okužbe z ošpicami se običajno pojavijo 10-12 dni po okužbi:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="206"> |
|
<prop type="lengthRatio">1.0588235294117647</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles spreads easily among unvaccinated individuals.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ošpice se med necepljenimi osebami hitro prenašajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="207"> |
|
<prop type="lengthRatio">1.0192307692307692</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Se pa antibiotiki pogosto uporabijo za zdravljenje zapletov bakterijskih okužb, ki lahko nastanejo pri ošpicah, kot sta pljučnica in vnetje srednjega ušesa.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="208"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kaj so ošpice?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="209"> |
|
<prop type="lengthRatio">0.8580645161290322</prop> |
|
<tuv xml:lang="en"> |
|
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Subakutni sklerozirajoči panencefalitis se običajno pojavi več let po tem, ko je prizadeti bolnik imel ošpice; v povprečju od sedem do deset let po okužbi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="210"> |
|
<prop type="lengthRatio">0.7490494296577946</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za preprečevanje nadaljnjega širjenja ošpic se uporabljajo najrazličnejši ukrepi, kot je karantena (začasna osamitev in odsotnost iz šole ali službe) okuženih oseb - in tudi tistih, ki so bili v tesnem stiku z bolnikom in niso bili uspešno zaščiteni s cepljenjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="211"> |
|
<prop type="lengthRatio">1.2035398230088497</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo OMR (ošpice, mumps in rdečke) je kombinirano cepivo, ki ščiti pred okužbo z ošpicami, mumpsom in rdečkami.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="212"> |
|
<prop type="lengthRatio">0.8333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pneumonia is the most common cause of measles-related death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zato je pljučnica tudi najpogostejši vzrok smrtnih primerovzaradi ošpic.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="213"> |
|
<prop type="lengthRatio">1.3148148148148149</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oseba z ošpicami je kužna že pred pojavom izpuščaja (običajno štiri dni) in še štiri dni po njegovem pojavu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="214"> |
|
<prop type="lengthRatio">0.8294573643410853</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ošpice so zelo nalezljiva virusna bolezen, s katero se je mogoče okužiti pri kateri koli starosti in se lahko zelo hitro prenaša.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="215"> |
|
<prop type="lengthRatio">0.9254658385093167</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri nekaterih cepljenih osebah se običajno od 7 do 14 dni po cepljenju pojavijo nenalezljivi, blagi, ošpicam podobni izpuščaji, ki po enem do treh dneh izginejo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="216"> |
|
<prop type="lengthRatio">0.52</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdo je izpostavljen tveganju za okužbo z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="217"> |
|
<prop type="lengthRatio">0.9253731343283582</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo OMR se lahko med izbruhi bolezni daje že pri nižji starosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="218"> |
|
<prop type="lengthRatio">0.78125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>začetni znaki so podobni nahodu (izcedek iz nosu, kašelj in rahlo povišana telesna temperatura);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="219"> |
|
<prop type="lengthRatio">1.03</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Virus ošpic se prenaša po zraku s kapljicami, ki jih s kašljanjem ali kihanjem izloči okužena oseba.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="220"> |
|
<prop type="lengthRatio">0.6756756756756757</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most people recover with supportive treatment, which can include hydration and anti-fever medicines.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Večina ljudi se pozdravi s podpornim zdravljenjem, kar lahko vključuje pitje dovolj tekočine in zdravila za zniževanje povišane telesne temperature.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="221"> |
|
<prop type="lengthRatio">0.5255972696245734</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Stopnja umrljivosti pri ošpicah je 1 do 3 osebe na 1 000 primerov okužbe, najvišja pa je pri otrocih, mlajših od pet let, in imunsko oslabljenih osebah.Pri približno vsakem tisočem bolniku pride do vnetja možgan (encefalitisa), ki pri enem od štirih primerov povzroči trajno nevrološko okvaro.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="222"> |
|
<prop type="lengthRatio">0.776</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Eden izmed možnih resnih zapletov okužbe z ošpicami je pljučnica, ki se lahko pri nekaterih bolnikih konča s smrtnim izidom .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="223"> |
|
<prop type="lengthRatio">0.6026490066225165</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Neželeni učinki, o katerih so poročali, so blage reakcije na cepivo, kot so povišana telesna temperatura ter rdečina ali oteklina na mestu injiciranja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="224"> |
|
<prop type="lengthRatio">1.1029411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>na dlesnih in v ustni sluznici se lahko pojavijo tudi belkaste lise.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="225"> |
|
<prop type="lengthRatio">0.9705882352941176</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so znaki okužbe z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="226"> |
|
<prop type="lengthRatio">1.0217391304347827</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These can include ear infections and diarrhoea.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med njimi so okužbe srednjega ušesa in driska.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="227"> |
|
<prop type="lengthRatio">1.16</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can measles be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se ošpice prenašajo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="228"> |
|
<prop type="lengthRatio">1.0555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="229"> |
|
<prop type="lengthRatio">0.8620689655172413</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Medicines Agency</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropska agencija za zdravila</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="230"> |
|
<prop type="lengthRatio">1.3524590163934427</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Je edina odgovorna za pripravo predlogov nove evropske zakonodaje ter izvaja odločitve Evropskega parlamenta in Sveta EU .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="231"> |
|
<prop type="lengthRatio">1.2982456140350878</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The European Commission is the EU's politically independent executive arm.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropska komisija je politično neodvisno izvršno telo EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="232"> |
|
<prop type="lengthRatio">0.9846153846153847</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These experts carry out the work of EMA's scientific committees.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ti strokovnjaki opravljajo delo znanstvenih odborov agencije EMA.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="233"> |
|
<prop type="lengthRatio">0.7777777777777778</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA je organizacija za mrežno povezovanje, v njene dejavnosti pa je vključenih na tisoče strokovnjakov iz vse Evrope.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="234"> |
|
<prop type="lengthRatio">0.9</prop> |
|
<tuv xml:lang="en"> |
|
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>(1) Evropska komisija, center ECDC in agencija EMA imajo na voljo mehanizme za zagotavljanje nepristranskosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="235"> |
|
<prop type="lengthRatio">0.8383838383838383</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The Commission is divided into departments that develop policies in specific areas.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Komisija je organizirana v obliki služb, ki so pristojne za razvoj politik po posameznih področjih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="236"> |
|
<prop type="lengthRatio">0.9811320754716981</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S tem je zagotovljeno, da se osebje in strokovnjaki pri opravljanju svojih nalog ne ukvarjajo z zadevami, v katerih bi lahko imeli posredni ali neposredni osebni interes, ki bi lahko zmanjšal njihovo neodvisnost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="237"> |
|
<prop type="lengthRatio">0.9904761904761905</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri razvoju vsebin sodelujejo strokovnjaki za komuniciranje in znanstveniki iz omenjenih organizacij (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="238"> |
|
<prop type="lengthRatio">0.9389312977099237</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA tesno sodeluje z evropskimi in mednarodnimi partnerji ter izmenjuje informacije o cepivih in dobri regulativni praksi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="239"> |
|
<prop type="lengthRatio">1.0658682634730539</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zajema tudi pregled ukrepov, ki se uporabljajo v Evropski uniji (EU) za zagotavljanje skladnosti razpoložljivih cepiv z najvišjimi standardi varnosti in učinkovitosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="240"> |
|
<prop type="lengthRatio">1.0229007633587786</prop> |
|
<tuv xml:lang="en"> |
|
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Center ECDC vzdržuje tudi Koledar cepljenj , interaktivno spletno platformo, ki prikazuje razporede cepljenja vseh držav članic EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="241"> |
|
<prop type="lengthRatio">0.7936507936507936</prop> |
|
<tuv xml:lang="en"> |
|
<seg>European Centre for Disease Prevention and Control</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropski center za preprečevanje in obvladovanje bolezni (ECDC)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="242"> |
|
<prop type="lengthRatio">0.890625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA zagotavlja učinkovitost, kakovost in varnost cepiv.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="243"> |
|
<prop type="lengthRatio">0.8547486033519553</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Osebje in strokovnjaki morajo predložiti izjavo o morebitnih osebnih interesih in interesih v katerem koli podjetju ali organizaciji, ki bi lahko ogrozili njihovo nepristranskost.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="244"> |
|
<prop type="lengthRatio">0.9815950920245399</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Agencija EMA in njeni znanstveni odbori preučijo vse razpoložljive podatke ter ocenijo koristi in tveganja cepiv pred odobritvijo in v času njihovega trženja v EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="245"> |
|
<prop type="lengthRatio">1.029535864978903</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>To spletno mesto je razvil Evropski center za preprečevanje in obvladovanje bolezni (ECDC) v sodelovanju z Evropsko komisijo, zlasti z Generalnim direktoratom a zdravje in varnost hrane (DG SANTE) ter Evropsko agencijo za zdravila (EMA).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="246"> |
|
<prop type="lengthRatio">0.9265536723163842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ena od teh služb je GD za zdravje in varnost hrane , ki je odgovoren za politiko EU na področju varnosti hrane in zdravja ter za spremljanje izvajanja s tem povezanih predpisov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="247"> |
|
<prop type="lengthRatio">1.092485549132948</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropska agencija za zdravila (EMA) je decentralizirana agencija Evropske unije (EU), ki je odgovorna za znanstveno vrednotenje, nadzor in spremljanje varnosti zdravil v EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="248"> |
|
<prop type="lengthRatio">0.9233449477351916</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Osrednje naloge zajemajo številne dejavnosti: spremljanje, epidemiološki podatki, odzivanje, znanstveni nasveti, mikrobiologija, pripravljenost, usposabljanje osebja v javnem zdravstvenem varstvu, mednarodni odnosi, komuniciranje v zvezi z zdravjem in znanstvena revija Eurosurveillance.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="249"> |
|
<prop type="lengthRatio">1.040983606557377</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Glavni namen tega spletnega mesta je zagotavljanje natančnih, objektivnih in posodobljenih dokazov o cepivih in cepljenju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="250"> |
|
<prop type="lengthRatio">1.0077519379844961</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več o tem: https://ec.europa.eu/health/vaccination/overview_en in https://ec.europa.eu/info/departments/health-and-food-safety_en</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="251"> |
|
<prop type="lengthRatio">0.9018181818181819</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na področju bolezni, ki jih je mogoče preprečiti s cepljenjem, center ECDC zagotavlja redne podatke o spremljanju, npr. število potrjenih primerov, in znanstvene nasvete o cepivih, spremlja izbruhe bolezni in pripravlja gradiva za podporo komuniciranju v zvezi z imunizacijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="252"> |
|
<prop type="lengthRatio">0.643312101910828</prop> |
|
<tuv xml:lang="en"> |
|
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Evropski center za preprečevanje in obvladovanje bolezni je znanstvena agencija EU, ki je odgovorna za krepitev evropske obrambe pred nalezljivimi boleznimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="253"> |
|
<prop type="lengthRatio">0.8669724770642202</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Namen pobude je odpraviti nezaupanje v cepljenje, izboljšati usklajevanje pri nabavi cepiv, podpreti raziskave in inovacije ter okrepiti sodelovanje v EU v boju proti boleznim, ki jih je mogoče preprečiti s cepljenjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="254"> |
|
<prop type="lengthRatio">0.9202453987730062</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri dokončnem oblikovanju vsebine spletnega mesta in njegovih jezikovnih različic so se posvetovali s predstavniki javnih zdravstvenih organizacij držav EU in EGP.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="255"> |
|
<prop type="lengthRatio">0.7746478873239436</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information visit: https://www.ema.europa.eu /</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dodatne informacije so na voljo na naslovu: https://www.ema.europa.eu /</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="256"> |
|
<prop type="lengthRatio">0.9396984924623115</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Spletno mesto je nastalo na pobudo Evropske unije in na podlagi Priporočila Sveta o okrepljenem sodelovanju v boju proti boleznim, ki jih je mogoče preprečiti s cepljenjem , sprejetega decembra 2018.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="257"> |
|
<prop type="lengthRatio">0.7746478873239436</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information visit: https://www.ecdc.europa.eu/</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dodatne informacije so na voljo na naslovu: https://www.ecdc.europa.eu/</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="258"> |
|
<prop type="lengthRatio">0.8928571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za izboljšanje precepljenosti je Svet decembra 2018 sprejel Priporočilo o okrepljenem sodelovanju v EU v boju proti boleznim, ki jih je mogoče preprečiti s cepljenjem .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="259"> |
|
<prop type="lengthRatio">1.2033898305084745</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They just take into account different circumstances and health systems.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Upoštevajo samo različne okoliščine in zdravstvene sisteme.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="260"> |
|
<prop type="lengthRatio">1.0340909090909092</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The differences between vaccination schedules do not mean that some are better than others.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Razlike med posameznimi koledarji cepljenj ne pomenijo, da so nekateri boljši od drugih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="261"> |
|
<prop type="lengthRatio">0.9130434782608695</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenja se glede na nacionalni koledar izvedejo v ustreznih časovnih presledkih, da se zagotovi ustrezna zaščita.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="262"> |
|
<prop type="lengthRatio">1.165938864628821</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dejavniki, ki vplivajo na te razlike, so lahko breme bolezni, razširjenost bolezni ter trendi v različnih državah, viri in strukture sistemov zdravstvenega varstva, politični in kulturni dejavniki ter prožnost programa cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="263"> |
|
<prop type="lengthRatio">0.9104938271604939</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Do razlik prihaja pri starosti in populaciji, ki jo je treba cepiti (na primer vsi otroci določene starosti ali samo tisti v ogroženi skupini), natančni vrsti cepiva (npr. določene sestavine se lahko razlikujejo), številu in časovnem razporedu odmerkov ter pri tem, ali se cepivo daje samostojno ali v kombinaciji z drugimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="264"> |
|
<prop type="lengthRatio">0.8922155688622755</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka država EU/EGP je odgovorna za svojo nacionalno politiko na področju javnega zdravja, vključno s svojim nacionalnim programom imunizacije in koledarjem cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="265"> |
|
<prop type="lengthRatio">1.0862068965517242</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The same level of protection is ensured in each EU/EEA country.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V vsaki državi EU/EGP je zagotovljena enaka raven varstva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="266"> |
|
<prop type="lengthRatio">0.9722222222222222</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination schedules in the EU/EEA</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Koledarji cepljenja v državah EU/EGP</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="267"> |
|
<prop type="lengthRatio">0.9101796407185628</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Obstajajo namreč določene razlike, kako države organizirajo svoj koledar cepljenja, zato so cepljenja v posameznih državah EU/EGP sicer podobna, vendar ne čisto enaka.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="268"> |
|
<prop type="lengthRatio">0.92</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Koledarji cepljenja za otroke v vseh državah EU/EGP vključujejo cepljenje proti naslednjim boleznim:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="269"> |
|
<prop type="lengthRatio">0.6951219512195121</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Informacije o nacionalnih koledarjih cepljenja v državah EU/EGP so na voljo v koledarju cepljenj Evropskega centra za preprečevanje in obvladovanje bolezni (ECDC) .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="270"> |
|
<prop type="lengthRatio">0.8148148148148148</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It can spread quickly.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Bolezen se zelo hitro širi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="271"> |
|
<prop type="lengthRatio">0.9393939393939394</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles had almost been eliminated in many European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ošpice so bile v številnih evropskih državah skoraj izkoreninjene.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="272"> |
|
<prop type="lengthRatio">1.1666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsako leto cepimo več sto milijonov ljudi po celem svetu za zaščito pred hudimi boleznimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="273"> |
|
<prop type="lengthRatio">1.0769230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V letu 2018 je na primer 86 % dojenčkov po vsem svetu prejelo tri odmerke cepiva za zaščito proti davici, tetanusu in oslovskemu kašlju (DTP), 85 % dojenčkov po vsem svetu pa tri odmerke cepiva proti otroški paralizi (1).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="274"> |
|
<prop type="lengthRatio">0.8295454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Bolezen lahko povzroči zelo krčevito kašljanje in običajno traja od treh do šest tednov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="275"> |
|
<prop type="lengthRatio">0.9494949494949495</prop> |
|
<tuv xml:lang="en"> |
|
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če bi prenehali s cepljenjem, bi se mnoge od teh bolezni in njihovi izbruhi lahko ponovno pojavili.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="276"> |
|
<prop type="lengthRatio">0.9882352941176471</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje proti oslovskemu kašlju je vključno v nacionalne programe imunizacije v EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="277"> |
|
<prop type="lengthRatio">1.02</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against measles is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Edina zaščita pred okužbo z ošpicami je cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="278"> |
|
<prop type="lengthRatio">0.4264705882352941</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Less than 5% will have fever.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri manj kot 5 % otrok se lahko pojavi povišana telesna temperatura.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="279"> |
|
<prop type="lengthRatio">1.1209677419354838</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Mnoge nalezljive bolezni so danes zelo redke prav po zaslugi cepljenja, zato včasih pozabimo na njihove negativne posledice.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="280"> |
|
<prop type="lengthRatio">0.9576271186440678</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepljenje preprečuje bolezni, ki bi sicer lahko povzročile resne zdravstvene težave, trajno invalidnost ali celo smrt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="281"> |
|
<prop type="lengthRatio">0.9426751592356688</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oboleli dojenčki v veliko primerih potrebujejo bolnišnično oskrbo, tveganje za zaplete in hospitalizacijo pa je večje pri dojenčkih, mlajših od treh mesecev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="282"> |
|
<prop type="lengthRatio">1.6521739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine is safe and effective.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Je varno in učinkovito.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="283"> |
|
<prop type="lengthRatio">0.813953488372093</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 20% of infants will have redness and pain at the injection site.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri približno 20 % dojenčkov se lahko pojavi rdečina in bolečina na mestu injiciranja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="284"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Toda od oktobra 2016 so se zaradi zmanjšane precepljenosti znova začele pojavljati v številnih državah članicah EU/EGP (2).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="285"> |
|
<prop type="lengthRatio">1.02</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med zapleti so lahko pljučnica, encefalopatija (obolenje možganov), epileptični napadi in celo smrt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="286"> |
|
<prop type="lengthRatio">0.75</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Measles can be serious or even life-threatening.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ošpice so lahko zelo resna ali celo življenjsko nevarna bolezen.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="287"> |
|
<prop type="lengthRatio">1.54</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo OMR ščiti proti ošpicam, mumpsu in rdečkam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="288"> |
|
<prop type="lengthRatio">1.6428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccinating</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Primer: ošpice</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="289"> |
|
<prop type="lengthRatio">0.6648648648648648</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za razliko od zdravil, ki se dajejo bolnim ljudem, se cepiva običajno dajejo zdravim ljudem, da bi preprečili bolezni, zato dolgoročne koristi cepljenja niso vedno vidne na prvi pogled.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="290"> |
|
<prop type="lengthRatio">1.2916666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj je bolezen, ki prizadene dihala.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="291"> |
|
<prop type="lengthRatio">1.0632911392405062</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Z njim zaščitimo otroke pred to boleznijo, njegovi neželeni učinki pa so blagi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="292"> |
|
<prop type="lengthRatio">0.6428571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see measles factsheet .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij je na voljo v informativnem listu o oslovskemu kašlju .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="293"> |
|
<prop type="lengthRatio">0.7833333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see pertussis factsheet .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij je na voljo v informativnem listu o ošpicah .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="294"> |
|
<prop type="lengthRatio">1.3478260869565217</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Primer: oslovski kašelj</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="295"> |
|
<prop type="lengthRatio">0.8823529411764706</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Decisions on vaccines in use in different European countries</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Odločanje o cepivih, ki se uporabljajo v različnih evropskih državah</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="296"> |
|
<prop type="lengthRatio">0.8739495798319328</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Takšna kombinirana uporaba cepiv je že uveljavljena in temelji na znanstvenih študijah o njihovih koristih in varnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="297"> |
|
<prop type="lengthRatio">0.9934640522875817</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka evropska država sama odloča, katera cepiva bodo vključena v njen nacionalni program cepljenja in financirana iz nacionalnega zdravstvenega sistema.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="298"> |
|
<prop type="lengthRatio">0.9856115107913669</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Večina nacionalnih programov cepljenja v državah EU/EGP vključuje cepiva proti največ dvajsetim boleznim, ki se dajejo v določeni starosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="299"> |
|
<prop type="lengthRatio">0.6621621621621622</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Takšne odločitve temeljijo na lokalnih razmerah v posamezni državi, kot je na primer pojavnost določene bolezni, pa tudi na gospodarskih dejavnikih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="300"> |
|
<prop type="lengthRatio">1.049689440993789</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij o nacionalnih programih cepljenja je na voljo v koledarju cepljenja centra ECDC in na uradnih spletiščih o imunizaciji držav članic EU/EGP tukaj .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="301"> |
|
<prop type="lengthRatio">1.1382978723404256</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Določena cepiva se včasih priporočajo tudi bolj ogroženim skupinam prebivalstva, kot so na primer osebe s kroničnimi obolenji ali ljudje, ki se odpravljajo na potovanje v druge dele sveta.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="302"> |
|
<prop type="lengthRatio">1.0987654320987654</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatera cepiva zagotavljajo zaščito samo proti eni, druga pa proti več boleznim.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="303"> |
|
<prop type="lengthRatio">0.9711538461538461</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Včasih je treba opraviti več cepljenj istočasno, da se vzpostavi zaščita proti več nalezljivim boleznim.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="304"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Thousands of volunteers</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na tisoče prostovoljcev</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="305"> |
|
<prop type="lengthRatio">0.9195402298850575</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ta program mora slediti postopkom in protokolom, ki so jih določili regulativni organi:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="306"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Is the vaccine safe?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ali je cepivo varno?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="307"> |
|
<prop type="lengthRatio">0.9066666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>njegove sestavine, vključno z neaktivnimi sestavinami ali pomožnimi snovmi;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="308"> |
|
<prop type="lengthRatio">0.8928571428571429</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is the optimal dose?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšen je optimalni odmerek?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="309"> |
|
<prop type="lengthRatio">0.9081632653061225</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V to so vključeni Evropska agencija za zdravila in drugi regulatorji v državah članicah EU in EGP.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="310"> |
|
<prop type="lengthRatio">1.3272727272727274</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How are the immune systems of the participants responding to the vaccine?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se imunski sistemi udeležencev odzivajo na cepivo?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="311"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Testing includes checking the vaccine's quality:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Preskušanje zajema preverjanje kakovosti cepiva:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="312"> |
|
<prop type="lengthRatio">1.0375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Temu sledi program kliničnega preskušanja pri ljudeh, ki lahko od začetnega koncepta do odobritve traja približno deset let in mora upoštevati stroge standarde.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="313"> |
|
<prop type="lengthRatio">0.8833333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This involves tests in the laboratory and in animals.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>To zajema preskuse v laboratorijih in testiranje na živalih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="314"> |
|
<prop type="lengthRatio">1.1320754716981132</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Razvijalec cepiva preskuša cepivo v treh fazah kliničnih preskušanj, v vsaki fazi z večjim številom ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="315"> |
|
<prop type="lengthRatio">0.8611111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Are there serious side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ali obstajajo resni neželeni učinki?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="316"> |
|
<prop type="lengthRatio">0.8742138364779874</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Regulativni organi za zdravila lahko izvajajo inšpekcijske preglede, s katerimi zagotovijo, da so informacije, ki jih zagotavlja razvijalec cepiva, zanesljive.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="317"> |
|
<prop type="lengthRatio">1.139240506329114</prop> |
|
<tuv xml:lang="en"> |
|
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ob koncu programa preskušanja razvijalec cepiva predloži rezultate regulativnim organom za zdravila v Evropi kot del vloge za pridobitev dovoljenja za promet.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="318"> |
|
<prop type="lengthRatio">1.0129870129870129</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Izvajajo lahko tudi preskuse, s katerimi zagotovijo, da so serije cepiv, ki se sprostijo na trg, pričakovane kakovosti in da so bile ustrezno proizvedene.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="319"> |
|
<prop type="lengthRatio">0.9748427672955975</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Regulativni organi lahko cepivo odobrijo le, če je iz znanstvene ocene rezultatov preskusov razvidno, da so njegove koristi večje od z njim povezanih tveganj .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="320"> |
|
<prop type="lengthRatio">0.9245283018867925</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the most common short-term side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kateri so najpogostejši kratkotrajni neželeni učinki?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="321"> |
|
<prop type="lengthRatio">0.9745222929936306</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Preden se cepivo lahko odobri v EU, mora najprej prestati zelo zahtevna preskušanja razvijalca cepiva in nato še znanstveno vrednotenje regulativnih organov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="322"> |
|
<prop type="lengthRatio">1.1702127659574468</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Then the vaccine developer tests the vaccine's effects.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Razvijalec cepiva nato preskusi njegove učinke.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="323"> |
|
<prop type="lengthRatio">0.95</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the most common side effects?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kateri so najpogostejši neželeni učinki?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="324"> |
|
<prop type="lengthRatio">1.1464968152866242</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Podjetja morajo na vsaki seriji cepiva, ki se sprosti na trg EU, izvesti zelo zahtevne preskuse, za katere so organi vnaprej določili merila sprejemljivosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="325"> |
|
<prop type="lengthRatio">0.8181818181818182</prop> |
|
<tuv xml:lang="en"> |
|
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nacionalne vlade pri tem upoštevajo različne dejavnike, kot so denimo njihovi zdravstveni sistemi, pravni sistemi in kulturne norme.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="326"> |
|
<prop type="lengthRatio">1.0909090909090908</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mandatory or recommended vaccination</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Obvezno ali priporočeno cepljenje</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="327"> |
|
<prop type="lengthRatio">0.8653846153846154</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country is responsible for its own national public health policy, including...</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka država EU/EGP je odgovorna za svojo nacionalno politiko na področju javnega zdravja, vključno s...</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="328"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Informacije o državah, ki imajo predpisana obvezna cepljenja, so na voljo v koledarju cepljenja .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="329"> |
|
<prop type="lengthRatio">1.24</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country implements its own immunisation programme.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka država EU/EGP izvaja svoj program cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="330"> |
|
<prop type="lengthRatio">0.9506172839506173</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V 12 državah članicah EU/EGP je cepljenje otrok proti nekaterim boleznim obvezno, pri čemer lahko vsaka država članica predpiše vrsto cepiva za obvezno cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="331"> |
|
<prop type="lengthRatio">1.018348623853211</prop> |
|
<tuv xml:lang="en"> |
|
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vse države članice EU/EGP so dosegle visoko stopnjo precepljenosti tako z neobveznim kot obveznim cepljenjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="332"> |
|
<prop type="lengthRatio">0.9347826086956522</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsaka država sama odloča o tem, katera cepljenja so obvezna ali neobvezna na njenem ozemlju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="333"> |
|
<prop type="lengthRatio">0.6702127659574468</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V večini držav članic EU/EGP je cepljenje neobvezno in se izvaja na osnovi uradnih priporočil.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="334"> |
|
<prop type="lengthRatio">1.0344827586206897</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Situation of measles in the EU</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Stanje na področju ošpic v EU</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="335"> |
|
<prop type="lengthRatio">0.8470588235294118</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Below are the most recent data on measles outbreaks in EU Member States.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nadaljevanju so navedeni najnovejši podatki o izbruhih ošpic v državah članicah EU.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="336"> |
|
<prop type="lengthRatio">1.0421052631578946</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Uporabniku omogoča filtriranje informacij na podlagi meril, kot sta bolezen in časovno obdobje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="337"> |
|
<prop type="lengthRatio">0.6010362694300518</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Podatki temeljijo na informacijah, ki so jih države članice predložile in preverile v okviru sistema za spremljanje bolezni pri Evropskem centru za preprečevanje in obvladovanje bolezni (ECDC).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="338"> |
|
<prop type="lengthRatio">0.8118279569892473</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Atlas za spremljanje nalezljivih bolezni, ki ga ponuja ECDC,zagotavlja tudi podatke o drugih boleznih, ki jih je mogoče preprečiti s cepljenjem, kot so davica, oslovski kašelj in rdečke.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="339"> |
|
<prop type="lengthRatio">1.072289156626506</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination also reduces the risk of spreading the diseases among family members, school mates or colleagues, friends and neighbours, as well as to other people in the community.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S cepljenjem se prav tako zmanjša tveganje širjenja bolezni med družinskimi člani, sošolci ali sodelavci, prijatelji, sosedi in drugimi pripadniki družbene skupnosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="340"> |
|
<prop type="lengthRatio">0.9915966386554622</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Thanks to vaccination, people can be protected against diseases that could have serious consequences for their health.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zahvaljujoč cepljenju lahko zaščitimo posameznike pred boleznimi, ki bi lahko imele resne posledice za njihovo zdravje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="341"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>More factsheets will be included at a later stage.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pozneje bodo dodani novi informativni listi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="342"> |
|
<prop type="lengthRatio">0.6206896551724138</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Disease factsheets</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Informativni listi o boleznih</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="343"> |
|
<prop type="lengthRatio">0.9950248756218906</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each factsheet provides key facts about a disease, with an overview of the symptoms, complications, how the disease spreads, who is at risk, how the disease can be prevented and how it can be treated.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na vsakem listu so navedena ključna dejstva o bolezni, skupaj s pregledom simptomov, zapletov, načinov prenosa bolezni, ogroženih skupinah ljudi, načinov za preprečevanje bolezni in načinov zdravljenja</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="344"> |
|
<prop type="lengthRatio">0.8870967741935484</prop> |
|
<tuv xml:lang="en"> |
|
<seg>To learn more about the diseases that can be prevented by vaccination, consult the factsheets available below.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če želite izvedeti več o boleznih, ki jih je mogoče preprečiti s cepljenjem, si oglejte spodaj priložene informativne liste.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="345"> |
|
<prop type="lengthRatio">1.0535714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Nowadays, several diseases can be prevented by vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Dandanes lahko s cepljenjem preprečimo številne bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="346"> |
|
<prop type="lengthRatio">0.8157894736842105</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Research is ongoing to develop vaccines against more diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Raziskave in razvoj novih cepiv proti mnogim drugim boleznim pa še potekajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="347"> |
|
<prop type="lengthRatio">0.8295454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Factsheets of five vaccine- preventable diseases are currently available.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Trenutno je na voljo gradivo o petih boleznih, ki jih je mogoče preprečiti s cepljenjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="348"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These include:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Mednje sodijo:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="349"> |
|
<prop type="lengthRatio">0.9743589743589743</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These substances are consistently controlled to ensure they are present at levels that have been shown to be safe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Te snovi so pod stalnim nadzorom za zagotovitev, da so prisotne v količinah, za katere je bilo dokazano, da so varne.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="350"> |
|
<prop type="lengthRatio">0.91</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Regulativni organi preverjajo, ali koristi teh sestavin odtehtajo tveganja morebitnih reakcij nanje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="351"> |
|
<prop type="lengthRatio">0.8641304347826086</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V cepivih se lahko v sledovih nahajajo tudi druge snovi, ki se uporabljajo v proizvodnem procesu, kot sta na primer ovalbumin (beljakovina v jajčnem beljaku) ali neomicin (antibiotik).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="352"> |
|
<prop type="lengthRatio">1.0266666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva poleg enega ali več antigenov cepiva vsebujejo tudi druge sestavine.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="353"> |
|
<prop type="lengthRatio">1.0136363636363637</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Whenever these substances are present at a level that might trigger a reaction in a sensitive or allergic individual, their presence is declared in the information provided to healthcare workers and patients on the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kadar koli so te snovi prisotne v količini, ki bi lahko sprožila reakcijo pri občutljivih ali alergičnih osebah, se vsebnost tovrstnih snovi navede v informacijah o cepivu, ki jih prejmejo zdravstveni delavci in bolniki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="354"> |
|
<prop type="lengthRatio">1.0582010582010581</prop> |
|
<tuv xml:lang="en"> |
|
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>pomožne snovi: neaktivne sestavine, kot so voda, natrijev klorid (sol) ter konzervansi ali stabilizatorji, ki so namenjeni temu, da ostane cepivo med shranjevanjem nespremenjeno in aktivno.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="355"> |
|
<prop type="lengthRatio">0.8713692946058091</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tako bo na primer v navodilu za uporabo navedeno, ali so potrebni posebni previdnostni ukrepi za uporabo cepiva pri ljudeh z določenimi alergijami, na primer pri ljudeh z alergijo na jajca, kadar gre za cepiva, ki vsebujejo jajca v sledovih.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="356"> |
|
<prop type="lengthRatio">0.9844961240310077</prop> |
|
<tuv xml:lang="en"> |
|
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>adjuvansi: snovi, ki spodbudijo imunski odziv na cepivo, zaradi česar je ta močnejši, hitrejši in trajnejši (na primer aluminij);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="357"> |
|
<prop type="lengthRatio">2.066666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Sestavine cepiv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="358"> |
|
<prop type="lengthRatio">1.0677966101694916</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Imunost običajno traja več let, včasih tudi celo življenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="359"> |
|
<prop type="lengthRatio">0.9</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is called the antigen.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Takšno snov imenujemo antigen.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="360"> |
|
<prop type="lengthRatio">0.7326732673267327</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Takšna „kolektivna imunost" je učinkovita samo takrat, kadar je cepljeno dovolj veliko število ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="361"> |
|
<prop type="lengthRatio">0.9122807017543859</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The length of time varies by disease and by vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Trajanje imunosti je za vsako bolezen in cepivo drugačno.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="362"> |
|
<prop type="lengthRatio">0.5945945945945946</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The person is also at risk of complications.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri takšni osebi obstaja tudi večje tveganje za morebitne zaplete bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="363"> |
|
<prop type="lengthRatio">0.859375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepiva vsebujejo bodisi zelo oslabljeno oziroma inaktivirano (neživo) obliko virusa ali bakterije, ki bi v običajni obliki lahko povzročila bolezen, ali pa majhen del virusa oziroma bakterije.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="364"> |
|
<prop type="lengthRatio">1.084848484848485</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S cepljenjem pridobljena imunost ne ščiti samo cepljene osebe, temveč tudi necepljene ljudi v njeni okolici, kot so denimo dojenčki, ki so še premajhni za cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="365"> |
|
<prop type="lengthRatio">0.8686131386861314</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo vzpodbudi odziv imunskega sistema in ustvari „spomin" v telesu človeka na določeno bolezen, brez da bi pri tem povzročilo bolezen.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="366"> |
|
<prop type="lengthRatio">1.0307692307692307</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vsak virus ali bakterija sproži enkraten odziv imunskega sistema, pri čemer igrajo pomembno vlogo posebne skupine celic v krvi, kostnem mozgu in celotnem telesu, imenovane celice T, celice B itd.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="367"> |
|
<prop type="lengthRatio">1.0588235294117647</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če cepljena oseba kasneje pride v stik z dejansko kužnim virusom ali bakterijo, se ju bo njen imunski sistem „spomnil".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="368"> |
|
<prop type="lengthRatio">0.9181286549707602</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tako bo lahko hitro začel tvoriti ustrezna protitelesa in aktiviral ustrezne imunske celice, ki bodo uničile virus ali bakterijo, s čemer bo zaščitil osebo bred boleznijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="369"> |
|
<prop type="lengthRatio">0.8</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibodies are special proteins that help kill the infectious agent.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Protitelesa so posebne beljakovine, ki pomagajo pri uničevanju povzročiteljev okužbe.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="370"> |
|
<prop type="lengthRatio">1.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ko oseba prejme cepivo, imunski sistem prepozna antigen kot „tujek".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="371"> |
|
<prop type="lengthRatio">0.8656716417910447</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za razliko od tega lahko oseba, ki preboleva bolezen, s katero se je okužila po naravni poti, izpostavi okužbi druge necepljene osebe.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="372"> |
|
<prop type="lengthRatio">0.900990099009901</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Imunske celice so izurjene za uničevanje povzročiteljev bolezni in za izdelavo protiteles proti njim.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="373"> |
|
<prop type="lengthRatio">2.3846153846153846</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Imunski odziv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="374"> |
|
<prop type="lengthRatio">0.7288135593220338</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They are also less likely to infect others.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prav tako obstaja manjša verjetnost, da bodo okužili druge.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="375"> |
|
<prop type="lengthRatio">0.9538461538461539</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Effectiveness in an individual depends on a number of factors.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Učinkovitost pri posameznikih je odvisna od številnih dejavnikov:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="376"> |
|
<prop type="lengthRatio">0.9347826086956522</prop> |
|
<tuv xml:lang="en"> |
|
<seg>other diseases or conditions they may have;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>drugih bolezni ali motenj, ki jih lahko imajo;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="377"> |
|
<prop type="lengthRatio">1.1333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>previous contact with the disease;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>predhodnega stika z boleznijo;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="378"> |
|
<prop type="lengthRatio">0.75</prop> |
|
<tuv xml:lang="en"> |
|
<seg>As with any medicine, no vaccine is 100% effective in every person vaccinated.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kot velja pri katerem koli zdravilu, tudi cepiva niso 100‑odstotno učinkovita pri vseh cepljenih osebah.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="379"> |
|
<prop type="lengthRatio">1.1603773584905661</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Do tega pride, kadar oseba ne razvije zadostne zaščite proti bolezni ali ker se imunost s časom zmanjšuje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="380"> |
|
<prop type="lengthRatio">0.9482758620689655</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In these cases, however, the person's symptoms are often milder than they would have been without vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vendar se v teh primerih simptomi pri posameznikih običajno pojavijo v blažji obliki, kot če ti ne bi bili cepljeni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="381"> |
|
<prop type="lengthRatio">1.128440366972477</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nekaterih primerih lahko posameznik še vedno zboli, čeprav je bil cepljen s priporočljivimi odmerki cepiva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="382"> |
|
<prop type="lengthRatio">0.5560344827586207</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo proti ošpicam, mumpsu in rdečkam (OMR) je na primer zelo učinkovito pri preprečevanju bolezni, saj običajno daje doživljenjsko zaščito in je pri zdravih otrocih, ki prejmejo dva odmerka, učinkovito v okoli 97 %-99 % primerov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="383"> |
|
<prop type="lengthRatio">1.1067961165048543</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kadar se odobrena cepiva pravilno uporabijo, učinkovito preprečujejo bolezni in zaščitijo prebivalstvo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="384"> |
|
<prop type="lengthRatio">0.9634146341463414</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Učinkovitost cepiva je odvisna od njegove zmožnosti, da prepreči določeno bolezen.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="385"> |
|
<prop type="lengthRatio">0.8571428571428571</prop> |
|
<tuv xml:lang="en"> |
|
<seg>the vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>cepiva samega.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="386"> |
|
<prop type="lengthRatio">1.2777777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccinating</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Učinkovitost cepiv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="387"> |
|
<prop type="lengthRatio">0.7352941176470589</prop> |
|
<tuv xml:lang="en"> |
|
<seg>how the vaccine is given;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>časa, ki je pretekel od cepljenja;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="388"> |
|
<prop type="lengthRatio">0.8387096774193549</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In healthy individuals it is usually a mild disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri zdravih ljudeh ta bolezen običajno poteka v blažji obliki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="389"> |
|
<prop type="lengthRatio">1.84</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Rubella (German measles) is a viral infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Rdečke so virusna okužba.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="390"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About us</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Rdečke</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="391"> |
|
<prop type="lengthRatio">0.6434108527131783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ošpice so zelo nalezljiva virusna bolezen, s katero se je mogoče okužiti pri kateri koli starosti in se lahko zelo hitro prenaša.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="392"> |
|
<prop type="lengthRatio">0.9868421052631579</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some countries such recommendations are done at state or regional level.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere državeizdajajo tovrstna priporočila nadržavni ali regionalni ravni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="393"> |
|
<prop type="lengthRatio">1.1782178217821782</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri iskanju informacij v zvezi z zdravjem je težko presoditi kakovost in točnost najdenih informacij.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="394"> |
|
<prop type="lengthRatio">0.9098360655737705</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They initially occur at night and then become more frequent during the day and may recur for one to two months.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Napadi se na začetku pojavljajo ponoči, nato postanejo pogostejši čez dan in se lahko ponavljajo od enega do dveh mesecev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="395"> |
|
<prop type="lengthRatio">1.141025641025641</prop> |
|
<tuv xml:lang="en"> |
|
<seg>People may wonder where to find accurate information, who is behind the development of the information they find, and also if the information is supported by scientific evidence.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Lahko se sprašujejo, kje je mogoče najti točne informacije, kdo je objavil informacije, ki jih najdejo, in ali so informacije podprte z znanstvenimi dokazi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="396"> |
|
<prop type="lengthRatio">0.928</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Tretji in četrti odmerek se priporočata pri starosti 11 do 24 mesecev, še en odmerek pa med tretjim in sedmim letom starosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="397"> |
|
<prop type="lengthRatio">0.9504950495049505</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines are not part of routine vaccination schedules but are targeted at specific groups.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatera cepiva niso del rutinskih programov cepljenja, saj so namenjena le določenim skupinam ljudi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="398"> |
|
<prop type="lengthRatio">1.0724637681159421</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Običajno se pojavi v nekaj minutah po izpostavljenosti viru alergije.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="399"> |
|
<prop type="lengthRatio">0.9698795180722891</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Mreža za varnost cepiva je globalna mreža spletnih mest, ki jo je vzpostavila Svetovna zdravstvena organizacija in zagotavlja zanesljive informacije o varnosti cepiv.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="400"> |
|
<prop type="lengthRatio">1.1944444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Official websites from EU and EEA countries</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Uradna spletna mesta držav EU in EGP</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="401"> |
|
<prop type="lengthRatio">0.9041916167664671</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zdravstveni delavci (npr. zdravniki, medicinske sestre) imajo posebno vlogo pri zagotavljanju, da bolniki v njihovi oskrbi pravočasno prejmejo priporočljivo cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="402"> |
|
<prop type="lengthRatio">0.8636363636363636</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In these groups, and in very young infants, pertussis is harder to diagnose.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri teh skupinah in pri zelo majhnih dojenčkih je oslovski kašelj težje diagnosticirati.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="403"> |
|
<prop type="lengthRatio">1.2920353982300885</prop> |
|
<tuv xml:lang="en"> |
|
<seg>After this phase, the coughing fits become less frequent and less severe, and the infant gradually gets better (this can take up to three months).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Po tej fazi so napadi kašlja manj pogosti in manj hudi, dojenček pa postopno okreva (kar lahko traja tri mesece).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="404"> |
|
<prop type="lengthRatio">0.9662921348314607</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Spodaj so povezave do uradnih spletnih strani z informacijami o cepljenju iz javnih zdravstvenih organizacij držav Evropske unije (EU) in Evropskega gospodarskega prostora (EGP).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="405"> |
|
<prop type="lengthRatio">0.8701298701298701</prop> |
|
<tuv xml:lang="en"> |
|
<seg>They also provide recommendations for people with chronic diseases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prav tako vsebujejo priporočila glede cepljenja ljudi s kroničnimi boleznimi.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="406"> |
|
<prop type="lengthRatio">0.9508196721311475</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Glavni namen tega spletnega mesta je zagotavljanje natančnih, objektivnih in posodobljenih dokazov o cepivih in cepljenju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="407"> |
|
<prop type="lengthRatio">1.2019230769230769</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Every effort should be made to see that women receive all routinely recommended vaccines before they reach child-bearing age.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prizadevati si je treba, da ženske prejmejo vsa rutinsko priporočena cepiva, preden dosežejo rodno dobo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="408"> |
|
<prop type="lengthRatio">0.910958904109589</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Priporočena so za različne starostne skupine, najpogosteje pri dojenčkih in otrocih, a tudi pri mladostnikih, odraslih osebah in starejših ljudeh.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="409"> |
|
<prop type="lengthRatio">1.0534351145038168</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Women of childbearing age should discuss with their healthcare provider which vaccines are recommended before, during and after pregnancy.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ženske v rodni dobi bi se morale s svojim zdravnikom pogovoriti, katera cepiva se priporočajo pred nosečnostjo, med njo in po njej.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="410"> |
|
<prop type="lengthRatio">0.9542857142857143</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Imunsko ogroženi bolniki imajo koristi tudi od tistih v njihovi bližini, ki so opravili vsa cepljenja (kot so družinski člani, negovalci), saj so tako tudi posredno zaščiteni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="411"> |
|
<prop type="lengthRatio">1.091549295774648</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere države priporočajo obnovitveni odmerek tudi za necepljene ženske kmalu po porodu, da se zmanjša tveganje prenosa bolezni na dojenčka.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="412"> |
|
<prop type="lengthRatio">1.0089285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Anafilaksa je redka, hitra, ekstremna alergijska reakcija, ki lahko povzroči šok, otekanje in težave z dihanjem.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="413"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In some cases, the completion of the immunisations needed is recommended prior to the start of a treatment, as during the treatment the patient may be at higher risks of infection.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V nekaterih primerih se priporoča dokončanje potrebnih cepljenj pred začetkom zdravljenja, saj lahko med zdravljenjem za bolnika obstaja večje tveganje za okužbo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="414"> |
|
<prop type="lengthRatio">1.078740157480315</prop> |
|
<tuv xml:lang="en"> |
|
<seg>With all the information that is available on the internet and circulating on social media on vaccination, people may sometimes get lost.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zaradi vseh informacij v zvezi s cepljenjem, ki so na voljo na spletu in krožijo po družbenih medijih, so ljudje lahko zmedeni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="415"> |
|
<prop type="lengthRatio">0.7551020408163265</prop> |
|
<tuv xml:lang="en"> |
|
<seg>When symptoms do occur, they include:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Če se simptomi pojavijo, ti običajno vključujejo:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="416"> |
|
<prop type="lengthRatio">1.3383458646616542</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, in order to be most effective, treatment must begin early in the course of disease, during the first one to two weeks before the episodes of numerous rapid coughs occur.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vendar se mora zdravljenje zaradi kar največje učinkovitosti začeti zgodaj, v prvem do drugem tednu, preden se začnejo napadi kašlja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="417"> |
|
<prop type="lengthRatio">0.7589285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antibiotics can be used to treat pertussis and prevent further spread of the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za zdravljenje oslovskega kašlja in preprečevanje nadaljnjega širjenja bolezni se lahko uporabljajo antibiotiki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="418"> |
|
<prop type="lengthRatio">1.009090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za določena cepiva lahko obstajajo tudi druge kontraindikacije, o katerih se je treba pogovoriti z zdravnikom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="419"> |
|
<prop type="lengthRatio">0.9583333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Približno 50 % oseb, okuženih z rdečkami, ne bo imelo nobenih simptomov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="420"> |
|
<prop type="lengthRatio">0.9625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Bolezen povzroča bakterija, ki je prisotna v ustih, nosu in žrelu okužene osebe.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="421"> |
|
<prop type="lengthRatio">1.0827067669172932</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Predhodne „anafilaktične" ali druge resne alergijske reakcije po prejemu cepiva so kontraindikacija za nadaljnje odmerke tega cepiva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="422"> |
|
<prop type="lengthRatio">0.7317073170731707</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some countries require proof of certain vaccinations before granting entry to the country.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere države namreč zahtevajo potrdilo o opravljenem cepljenju proti določenim boleznim, preden dovolijo vstop v državo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="423"> |
|
<prop type="lengthRatio">0.9117647058823529</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For example, people who travel to regions where certain infectious diseases circulate such as yellow fever and typhoid fever may need to have vaccinations.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na primer, potniki, ki potujejo na območja, kjer so prisotne določene nalezljive bolezni, kot sta na primer rumena mrzlica in trebušni tifus, se bodo morda morali cepiti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="424"> |
|
<prop type="lengthRatio">1.349056603773585</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prenaša ga lahko tudi oseba, ki ima samo blažjo obliko bolezni, ali okužena oseba, ki nima nobenih znakov.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="425"> |
|
<prop type="lengthRatio">0.8346456692913385</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Mladostniki, odrasli in otroci, ki še niso bili cepljeni z vsemi odmerki, imajo običajno blažje ali nekoliko drugačne simptome.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="426"> |
|
<prop type="lengthRatio">0.9112426035502958</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere države EU/EGP priporočajo obnovitveni odmerek cepiva za mladostnike, odrasle in/ali nosečnice, saj tak odmerek pri nosečnicah začasno zaščiti tudi novorojenčka.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="427"> |
|
<prop type="lengthRatio">0.9926470588235294</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Ženske, ki načrtujejo zanositev, naj predhodno preverijo svoj cepilni status, saj med nosečnostjo cepiva proti rdečkam ne smejo prejeti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="428"> |
|
<prop type="lengthRatio">0.8726708074534162</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatere motnje imunskega sistema (npr. kongenitalne imunske pomanjkljivosti) ali zdravljenja (npr. kemoterapija, presaditev kostnega mozga ali drugega organa oziroma visoki odmerki steroidov) so kontraindikacije za nekatera cepiva, kot sta cepivo proti ošpicam, mumpsu, rdečkam, noricam ali peroralno cepivo proti tifusu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="429"> |
|
<prop type="lengthRatio">0.95260663507109</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Someone who experiences an anaphylactic or other serious allergic reaction following a certain vaccine should not be given that vaccine again, unless the vaccine is definitively ruled out as the cause.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oseba, ki je imela anafilaktično ali drugo hudo alergijsko reakcijo po cepljenu z določenim cepivom i, ne sme ponovno prejeti tega cepiva, razen če je cepivo nedvomno izključeno kot vzrok za alergijsko reakcijo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="430"> |
|
<prop type="lengthRatio">0.9850746268656716</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri mlajših dojenčkih se značilno piskajoči zvok lahko nikoli ne razvije, napadom kašlja pa lahko sledijo krajša obdobja brez dihanja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="431"> |
|
<prop type="lengthRatio">1.1058823529411765</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Znaki okužbe se običajno pojavijo od 7 do 10 dni po okužbi, lahko pa tudi po 21 dneh.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="432"> |
|
<prop type="lengthRatio">0.8321167883211679</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Informacije in povezave do spletnih mest članov mreže za varnost cepiva je na voljo tukaj: https://www.vaccinesafetynet.org/vsn/network .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="433"> |
|
<prop type="lengthRatio">0.9746835443037974</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The most important way to prevent pertussis is through complete immunisation.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Najpomembnejši način za preprečevanje oslovskega kašlja je popolna imunizacija.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="434"> |
|
<prop type="lengthRatio">1.1953125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V dveh tednih postane kašelj hujši, značilni so napadi kašlja, ki ga spremlja vreščeč ali visok piskajoči zvok, podoben riganju.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="435"> |
|
<prop type="lengthRatio">0.8285714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>National vaccination schedules in EU/EEA countries recommend vaccines at specific ages and for specific populations.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nacionalni koledarji cepljenja v državah članicah EU/EGP priporočajo cepljenje določenih starostnih skupin in določenih skupin prebivalstva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="436"> |
|
<prop type="lengthRatio">0.985</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo proti oslovskemu kašlju se običajno kombinira s cepivom proti davici in tetanusu (pogosto tudi v kombinaciji s cepivom proti otroški paralizi, bakteriji Haemophilus influenzae in hepatitisu B).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="437"> |
|
<prop type="lengthRatio">1.0075757575757576</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Med zapleti pri odraslih in starejših otrocih so lahko krajša obdobja prenehanja dihanja, zlomljena rebra, prolaps danke in hernije.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="438"> |
|
<prop type="lengthRatio">1.441860465116279</prop> |
|
<tuv xml:lang="en"> |
|
<seg>swollen lymph glands around the ears and the back of the head;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>otekle bezgavke na območju ušes in zatilja;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="439"> |
|
<prop type="lengthRatio">0.8323353293413174</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine is contraindicated to those allergic to any of the vaccine active substances or ingredients as listed in the product information.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo je kontraindicirano pri ljudeh, ki so alergični na katero koli učinkovino ali sestavino cepiva, kot je navedeno v informacijah, ki so priloženepripravku cepiva.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="440"> |
|
<prop type="lengthRatio">1.6419753086419753</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Frequently, older siblings and parents who may be carrying the bacteria bring the disease home and infect an infant in the household.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pogosto bolezen prinesejo starejši sorojenci ali starši in doma okužijo dojenčka.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="441"> |
|
<prop type="lengthRatio">0.87</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Nekatera cepiva so kontraindicirana med nosečnostjo, kot je cepivo proti ošpicam, mumpsu in rdečkam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="442"> |
|
<prop type="lengthRatio">0.9855072463768116</prop> |
|
<tuv xml:lang="en"> |
|
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Toda če za njo zboli nosečnica v prvem tromesečju, je zelo velika verjetnost, da se bo nosečnost končala s splavom oziroma da bo otrok imel prirojene nepravilnosti, ki jih imenujemo sindrom prirojenih rdečk.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="443"> |
|
<prop type="lengthRatio">0.9880952380952381</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The first dose is given between 10 and 18 months of age in most European countries.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Prvi odmerek se v večini evropskih držav daje, ko je otrok star od 10 do 18 mesecev.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="444"> |
|
<prop type="lengthRatio">0.8620689655172413</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The most severe forms of pertussis are in infants.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za najhujšimi oblikami oslovskega kašlja zbolijo dojenčki.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="445"> |
|
<prop type="lengthRatio">1.0384615384615385</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This section provides links to the websites of other health organisations both at national and international level, in order to facilitate access to trusted sources of information, such as:</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Za olajšanje dostopa do zanesljivih virov informacij so v tem razdelku navedene povezave do spletnih strani drugih zdravstvenih organizacij na nacionalni in mednarodni ravni, kot je:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="446"> |
|
<prop type="lengthRatio">0.8195488721804511</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Na začetku bolezni so znaki podobni navadnemu prehladu (kihanje, izcedek iz nosu, rahlo povišana telesna temperatura in blag kašelj).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="447"> |
|
<prop type="lengthRatio">0.9736842105263158</prop> |
|
<tuv xml:lang="en"> |
|
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Njegove posledice so lahko gluhota, katarakta in razvojne težave pri otroku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="448"> |
|
<prop type="lengthRatio">0.8947368421052632</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis in unvaccinated infants or infants whose mother was unvaccinated can be particularly severe.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj je lahko posebno resen pri necepljenih dojenčkih ali dojenčkih, katerih matere niso bile cepljene.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="449"> |
|
<prop type="lengthRatio">0.9021739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj je zelo nalezljiva bakterijska bolezen, ki prizadene pljuča in dihalne poti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="450"> |
|
<prop type="lengthRatio">1.0957446808510638</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Posledice okužbe z rdečkami pri necepljenih nosečnicah so zelo resne, saj je zelo verjetno, da bo posledica take okužbe med nosečnostjo splav ali sindrom prirojenih rdečk pri novorojenčku.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="451"> |
|
<prop type="lengthRatio">0.9006211180124224</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri nekaterih cepljenih osebah se običajno od 7 do 14 dni po cepljenju pojavijo nenalezljivi, blagi, ošpicam podobni izpuščaji, ki po enem do treh dneh izginejo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="452"> |
|
<prop type="lengthRatio">1.0736842105263158</prop> |
|
<tuv xml:lang="en"> |
|
<seg>These episodes frequently end with the expulsion of a thick, clear mucous, often followed by vomiting.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Po končanih napadih bolnik večkrat izkašlja gosto, prozorno sluz, čemur pogosto sledi bruhanje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="453"> |
|
<prop type="lengthRatio">1.069767441860465</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pain and inflammation of the joints in adults.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>boleče in vnete sklepe pri odraslih osebah.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="454"> |
|
<prop type="lengthRatio">1.0530973451327434</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Cepivo OMR (ošpice, mumps in rdečke) je kombinirano cepivo, ki ščiti pred okužbo z ošpicami, mumpsom in rdečkami.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="455"> |
|
<prop type="lengthRatio">2.1868131868131866</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>O možnih kontraindikacijah se je treba pred prejemom cepiva vedno posvetovati z zdravnikom.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="456"> |
|
<prop type="lengthRatio">0.8402777777777778</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vse osebe, ki te bolezni še niso prebolele ali niso bile cepljene proti njej s cepivom OMR, so izpostavljene tveganju za okužbo z virusom rdečk.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="457"> |
|
<prop type="lengthRatio">1.1014492753623188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij o mreži je na voljo na: https://vaccinesafetynet.org .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="458"> |
|
<prop type="lengthRatio">1.02</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The only protection against rubella is vaccination.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Edina zaščita pred okužbo z rdečkami je cepljenje.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="459"> |
|
<prop type="lengthRatio">0.9857142857142858</prop> |
|
<tuv xml:lang="en"> |
|
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>V skladu z nacionalnim programom cepljenja otroci prvega od dveh do treh odmerkov običajno dobijo med drugim in dvanajstim mesecem starosti.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="460"> |
|
<prop type="lengthRatio">0.56</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdo je izpostavljen tveganju za okužbo z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="461"> |
|
<prop type="lengthRatio">0.9423076923076923</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Najpogostejši zapleti so pljučnica, encefalopatija (možganska bolezen), epileptični napadi in celo smrt.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="462"> |
|
<prop type="lengthRatio">1.9473684210526316</prop> |
|
<tuv xml:lang="en"> |
|
<seg>PLoS Med. 2013 Nov; 10(11): e1001558.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Protitelesa&nbsp;3.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="463"> |
|
<prop type="lengthRatio">1.146341463414634</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information, see pertussis factsheet .</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Drugo ime za oslovski kašelj je pertusis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="464"> |
|
<prop type="lengthRatio">0.9183673469387755</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij je na voljo na spletišču centra ECDC: https://www.ecdc.europa.eu/en/pertussis/facts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="465"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Rdečke se širijo po zraku z drobnimi kapljicami, ki jih s kašljanjem ali kihanjem izloči okužena oseba.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="466"> |
|
<prop type="lengthRatio">1.0294117647058822</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so znaki okužbe z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="467"> |
|
<prop type="lengthRatio">0.7073170731707317</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can measles be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se zaščititi pred okužbo z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="468"> |
|
<prop type="lengthRatio">0.8383838383838383</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Oslovski kašelj se prenaša po zraku s kužnimi kapljicami, ki jih s kašljanjem izloči okužena oseba.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="469"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of pertussis?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe z ošpicami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="470"> |
|
<prop type="lengthRatio">1.3653846153846154</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Zboli lahko vsakdo, ki ni cepljen proti oslovskemu kašlju ali ni cepljen v skladu s programom cepljenja.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="471"> |
|
<prop type="lengthRatio">0.8918918918918919</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so simptomi okužbe z rdečkami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="472"> |
|
<prop type="lengthRatio">0.8064516129032258</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is the optimal dose?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se oslovski kašelj zdravi?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="473"> |
|
<prop type="lengthRatio">1.09</prop> |
|
<tuv xml:lang="en"> |
|
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Več informacij je na voljo na spletišču centra ECDC: https://www.ecdc.europa.eu/en/rubella/factsheet</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="474"> |
|
<prop type="lengthRatio">1.8461538461538463</prop> |
|
<tuv xml:lang="en"> |
|
<seg>An example is aluminium;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Imunski odziv</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="475"> |
|
<prop type="lengthRatio">1.0416666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Monitoring vaccine safety & reporting side effects</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>mreža za varnost cepiva (The Vaccine Safety Net)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="476"> |
|
<prop type="lengthRatio">0.7073170731707317</prop> |
|
<tuv xml:lang="en"> |
|
<seg>How can rubella be prevented?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kako se zaščititi pred okužbo z rdečkami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="477"> |
|
<prop type="lengthRatio">0.52</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Who is at risk of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kdo je izpostavljen tveganju za okužbo z rdečkami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="478"> |
|
<prop type="lengthRatio">1.0555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the complications of rubella?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe z rdečkami?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="479"> |
|
<prop type="lengthRatio">0.7333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What are the symptoms of measles?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kakšni so zapleti okužbe z oslovskim kašljem?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="480"> |
|
<prop type="lengthRatio">0.888</prop> |
|
<tuv xml:lang="en"> |
|
<seg>This website does not contain any specific information on the ongoing development of vaccines against COVID-19.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Danes imamo na voljo cepiva za številne bolezni, raziskave za razvoj novih cepiv proti mnogim drugim boleznim pa še potekajo.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="481"> |
|
<prop type="lengthRatio">1.0638297872340425</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Vir: Plotkin S, Orenstein W, Offit P. Vaccines.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="482"> |
|
<prop type="lengthRatio">0.9565217391304348</prop> |
|
<tuv xml:lang="en"> |
|
<seg>fever or feverishness;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>vročina ali vročičnost;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="483"> |
|
<prop type="lengthRatio">0.9629629629629629</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Human papillomavirus (HPV)</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Humani papiloma virus (HPV)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="484"> |
|
<prop type="lengthRatio">0.9021739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>S cepljenjem lahko bolezni izkoreninimo ali znatno zmanjšamo število novih primerov bolezni.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="485"> |
|
<prop type="lengthRatio">1.013157894736842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Stopnja umrljivosti pri ošpicah je 1 do 3 osebe na 1 000 primerov okužbe, najvišja pa je pri otrocih, mlajših od pet let, in imunsko oslabljenih osebah.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="486"> |
|
<prop type="lengthRatio">0.6764705882352942</prop> |
|
<tuv xml:lang="en"> |
|
<seg>time since vaccination;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>časa, ki je pretekel od cepljenja;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="487"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Pri približno vsakem tisočem bolniku pride do vnetja možgan (encefalitisa), ki pri enem od štirih primerov povzroči trajno nevrološko okvaro.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="488"> |
|
<prop type="lengthRatio">1.21875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for individuals</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Koristi cepljenja za posameznike</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="489"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>how the vaccine is given;</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>načina dajanja cepiva;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="490"> |
|
<prop type="lengthRatio">1.3846153846153846</prop> |
|
<tuv xml:lang="en"> |
|
<seg>What is influenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Kaj je gripa?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="491"> |
|
<prop type="lengthRatio">1.4137931034482758</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Benefits of vaccination for the community</seg> |
|
</tuv> |
|
<tuv xml:lang="sl"> |
|
<seg>Koristi cepljenja za skupnost</seg> |
|
</tuv> |
|
</tu> |
|
</body> |
|
</tmx> |
|
|
